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Design and Combinatorial Synthesis Approach of Non-peptidic Trimeric Small
Molecules Mimicking i, i +4(3), i +7 Positions of -Helices
Mingzhou Zhou
Abstract
Protein-protein interactions are key to several biological processes that facilitate signal
transduction and many other processes. These interactions are involved in pathways that
are critical to many human diseases. Targeting specific protein-protein interactions is a
challenging goal because protein-protein interactions are predominately through
hydrophobic interactions. Antagonists of the protein-protein interactions need to be
perfectly fit into the binding pockets to ensure the activity. The -helical domain of the
proteins behaves as the recognition motifs for numerous protein-protein, and proteinnucleic acid interactions. Research has shown that pathways of many diseases contain
protein-protein interactions involving -helical domains, e.g. neurological disorders,
bacterial infections, HIV and cancer, etc. It is difficult yet very important to design small
molecules to target the shallow binding areas of protein-protein interactions. So far the
most successful one is Hamilton’s 1,4-terphenylene scaffold, which has been used to
target the interactions between p53/MDM2, Bak/Bcl-xL etc.

Inspired by this, we

designed and synthesized three new scaffolds of non-pepditic -helical mimetics,
mimicking the i, i + 4, i + 7 positions of an -helix. There are three basic principles that
were leading our design. The side chains of our designed molecules should act as
mimetics of the side chains of an -helix. Second, our molecules should possess
xiii

improved water solubility. Third, the molecules should be easy to synthesize to generate
a focused library. Some of our molecules, including the ones whose molecular weight
are as low as 294, started to show some inhibition against p53/MDM2 interactions.

xiv

Chapter One:
Peptidic and Non-peptidic Scaffolds to Disrupt Protein-protein Interactions that
Involve -Helices
1.1

Protein-protein interactions
Protein-protein interactions are key to several biological processes that facilitate

signal transduction and many other processes.

These interactions are involved in

pathways that are critical to many human diseases. By disrupting certain protein-protein
interactions, we are able to gain an understanding of functions of individual proteins and
their roles in the biological system; most importantly, this allows us to gain an
understanding of the role of specific proteins in disease pathways.
1.2

Efforts to target the protein-protein interaction
Targeting specific protein-protein interactions is a challenging goal because

unlike the interactions between the enzymes and their substrates which contain many
hydrogen bonds, protein-protein interactions are predominately through hydrophobic
interactions. Antagonists of the protein-protein interactions need to be perfectly fit into
the binding pockets to ensure the activity. Unfortunately, the binding areas on the
proteins are normally shallow and large (Stites, 1997), unlike that of the enzymes; this
makes the design of small molecule antagonists that can disrupt protein-proteins
interactions even more difficult (Ernst et al., 2003). Screening chemical libraries has not
1

been particularly successful in this area (Kutzki et al., 2002). However, rational design
has proven to be a more suitable approach (Yin and Hamilton, 2005). Rational design is
a more successful procedure because the binding sites of the protein-protein interactions
are normally well-defined three-dimensional surfaces; hence, molecules with these
properties have the most potential to serve as protein-protein interaction inhibitors.
Protein-protein interactions occur on shallow surface features of the protein;
typically, the binding areas contain only a limited amount of crucial amino acid residues.
The most rational way to disrupt these interactions is to design and synthesize molecules
that are capable of mimicking the three dimensional configuration of those crucial amino
acids side chains.
The two essential factors in designing small molecule protein-protein interaction
antagonists are to identify the three dimensional configurations of the crucial binding
amino acids of the target interactions and to design scaffolds that could hold the
functional groups at specific locations.
1.3

Efforts to target the protein-protein interactionsinvolving -helix
One of the most important and abundant protein secondary structures is the -

helix.

The -helical domain of the proteins behaves as the recognition motifs for

numerous protein-protein interactions, protein-DNA interactions, and protein-RNA
interactions (Lavery, 2005); (Klug, 2005). Research has shown that pathways of many
diseases contain protein-protein interactions involve -helical domains (Table 1.1)
(Davis et al., 2007).

2

A typical -helix has a structural domain, which is about 15 – 25 residues in
length (Garner and Harding, 2007). The -helix residue peptides when excised from
their parent proteins cannot retain their secondary structures (Kelso and Fairlie, 2003). In
addition, the excised peptides, in vivo, could not bind to their target protein any more.
This is the reason why we cannot use the -helix sequence directly as the antagonist for
protein-protein interactions.
Table 1.1: Typical disease pathways that involve the interaction of -helix
ppi
Tachykinin receptors/peptide
NaIP
gp41
p53/MDM2
smMLCK/CaM
Rac1/Tiam1
GRIP1/Era
Vav

diseases
neurological disorders
bacterial infections
HIV
cancer
cancer
cancer
cancer
cancer

motif
i, i + 4
i, i + 4, i + 7
i, i + 3, i + 4, i + 7
i, i + 4, i + 7
i, i + 4, i + 7
i, i + 4, i + 7
i, i + 3, i + 4
i, i + 1, i + 4

Bak/Bcl-xL

cancer

i, i + 4, i + 7, i + 11

Due to the importance of the -helix in the field of protein-protein interactions,
extensive research has focused on the design and synthesize of -helical mimetics.
Studies of -helical mimetics are important because it can help us understand the roles
that -helices play in protein-protein interactions.
1.4

Peptidic -Helical mimetics

3

-Helices are the secondary structures of peptide chains; thus, it is
straightforward to design their mimetics using peptides. As a matter of fact, peptidic helical mimetics are a successful approach toward mimicking -helical protein-protein
interactions.
1.4.1

Cyclic peptides
Despite the fact that many peptidic -helical mimetic scaffolds have been

developed, the strategy is similar. As discussed above, short peptide chains are prone to
remain unfolded, even though the same primary sequences form -helices in proteins.
To make short stable peptide -helices, the peptides could be cyclized so that their
conformational flexibility is locked. In other words, cyclization of peptides is the most
common strategy that peptide chemists use to stabilize short chain peptides to form helices.
The peptide cyclization strategy is a simple procedure. Because the side chains of
the amino acid residues of an -helix at the i, i + 4, i + 7, i + 11 positions are on the same
face, if we connect two side chains among the i and the i + 4, i + 7, and i + 11 positions
of an unfolded peptide, with proper length linker, to force them be on the same face, the
peptide is stabilized as an -helical conformation. There are three major methodologies
that have been developed following this strategy.
1.4.2

Direct covalent bonding of the side chains of the amino acids

4

There are two kinds of covalent bonds that could be directly formed between the
side chains of the natural amino acids: amide bonds between lysine and aspartic acid /
glutamic acid (Condon et al., 2000), and disulfide bonds between two cysteines (Jackson
et al., 1991) (Figure 1.1).

Figure 1.1: Covalent bonding cyclic peptides
The synthesis of these kinds of cyclic peptides is convenient because coupling of
side chains of lysine and aspartic acid / glutamic acid forms an amide bond and the
oxidation of two sulfides on cysteine side chains forms a disulfide bond.
It has been reported that this direct covalent bonding methodology has been
utilized to make the smallest -helical peptide in water (Figure 1.2) (Shepherd et al.,
2005). However, this is also the limitation of using direct covalent bonding. The side
chains of the amino acid have limited length; consequently, this method could not be
used to make larger -helical regions. When a relatively longer unfolded -helical
peptide chain has been cyclized using this method, only the cyclized small region could
be an -helix (Garner and Harding, 2007).
5

Figure 1.2: The smallest reported -helical peptide in water and its conformation
determined by NMR
1.4.3

Metal coordinate bonding
Besides the direct covalent bonding between the side chains of two amino acids,

coordinate bond was used to connect the side chains (Figure 1.3) (Kelso et al., 2003);
(Kelso et al., 2004); (Beyer et al., 2004).

Figure 1.3: Metal coordinate bonding cyclic peptides
Transition metals, such as palladium, zinc, etc. were used to form the coordinated
bonds with side chains of histidine / cysteine at i, i + 4 positions (Figure 1.3).
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Like the direct covalent bonding, only small -helical regions could be formed by
metal coordinate bonding. Also, these cyclic peptides are not stable in water. However,
it provides one other possible way to form an -helix; especially since metal ions play
important roles in biological systems.
1.4.4

Connecting side chains of unnatural amino acids at i and i + 7 positions.
All natural amino acids have side chains which are short in length. This limits the

potential size of the cyclic peptide if we choose to directly connect the side chains. There
are two ways to solve this problem; one is to use unnatural amino acids with longer side
chains, or longer linkers can be used.
For the first way, unnatural amino acids were used, which have extended side
chains (5 to 8 carbons-carbon single bond’s in length) introduced at the i and i + 7
positions (Figure 1.4) (Blackwell and Grubbs, 1998); (Blackwell et al., 2001).

Figure 1.4: Cyclic peptide formed by unnatural amino acids
Carbon-carbon double bonds were used to connect the side chains. Although
stable in water, amide bonds and disulfide bonds are ruled out because they are prone to
7

be degraded in biological systems. In summary, two amino acids that have side chains
with an alkene group at the terminal position are introduced to the peptide scaffold
through the Grubbs metathesis coupling reaction.
1.4.5

Connecting i and i + 7 side chains with a photo-controlled azobenzene linker
The second strategy to form a bigger -helical region is to use longer linkers to

connect the i and i + 7 positions. Azobenzene was chosen as this linker because of its
length and its photo sensitive isomerization (Woolley, 2005); (Ihalainen et al., 2007).
The azobenzene linker was connected to the peptide by the help of a sulfur atom
at the side chains of the cysteine. One unique property of azobenzene is that its nitrogennitrogen double bond isomerizes under different conditions (Figure 1.5); the distance
between 4 and 4’ position of the benzene rings changes greatly between cis and trans
double bonds. The azobenzene linker was designed so that, when the nitrogen-nitrogen
double bond is in the cis configuration, the peptide will be stabilized as an -helix.

Figure 1.5: Conformational change of cyclic peptide following the change of nitrogennitrogen double bond conformation
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However, when the double bond is in trans configuration, the peptide chains would be
unable to maintain the -helical secondary structure.
The azobenzene linker strategy is one method that can control the conformation of
a peptide chain after the peptide has been cyclized; thus could be applied to understand
the roles that -helices play.
1.5

Miniproteins
Short peptide sequences taken from a protein tend to lose their secondary

structures.

This also suggests that although the other part of the protein does not

participate in the bonding interaction, it helps stabilize the protein secondary structure. If
a second protein was introduced to stabilize the short peptide chain, will the peptide
reform its secondary structure?

Figure 1.6: Short chain -helix stabilized by mimiprotein

9

Following this question, miniproteins were designed to stabilize the non-bonding
face of a -helix through protein-protein interactions, so that a short peptide chain will
form its secondary structure (Figure 1.6) (Chin and Schepartz, 2001); (Rutledge et al.,
2003).
Miniproteins are small proteins that have well defined secondary structures. They
can recognize and interact with short peptide chains, forcing the peptide chains to form
secondary structures, normally an -helix.

The now well-assembled short peptides

behave like the -helical domains in the proteins to recognize their targets.
1.6

Foldamers

Figure 1.7: Examples of foldamers
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Foldamers are oligomers have well-defined secondary structures stabilized by
non-covalent bonding. The peptidic foldamers use unnatural peptidic building blocks,
such as -peptides, -peptides,-peptides, peptoid, and oligourea, etc.

(Figure 1.7)

(Werder et al., 1999); (Cheng, 2004); (Kritzer Joshua et al., 2005).
Foldamers not only have secondary structures similar to -helix (Figure 1.8), but
are also capable of disrupting protein-protein interactions involving -helices.

Figure 1.8: Comparison of -helix and -peptide helix
1.7

Synthetic non-peptidic -helical mimetics with linear scaffold
Besides the peptidic approach to mimic the -helices, organic chemists have built

small molecular (<750 Da) scaffolds in this field. Until now, most drugs on the market
are small synthetic molecules. Small molecules have several advantages to serve as the
drug molecules, such as being more stable and more membrane permeable.
It is difficult for small molecules to target the shallow binding areas of proteinprotein interactions; it is even more difficult for them to mimic the complicated surface
11

areas of -helices. This might be the reason why the first synthetic non-peptidic helical mimetic small molecules (Figure 1.9) were not reported until 2001 (Garner and
Harding, 2007).

Figure 1.9: First reported synthetic non-peptidic -helical mimetics
Hamilton and coworkers were the first to publish synthetic small molecular nonpeptidic -helical mimetic scaffold, 1,4-terphenylene (Orner et al., 2001). Although the
surface of an -helix is complicated, its binding site is along one face of the -helix.
Therefore, we just need to design molecules to mimic that face of the -helix. Also, an
-helix has a coil-like backbone; and its configuration is rigid, regardless of the amino
acid residues. This means that only residues lined in certain primary structures sequence
(e.g. i, i + 3, i + 4; i, i + 3, i + 7; i, i + 4, i + 7; i, i + 4, i + 7, i + 11) (Figure 1.10) could be
on the same face with each other. Thus, the amino acid residues on one face of the helix should have fixed relative geometric locations to each other.
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Figure 1.10: Model of a typical -helix (NIH)
The relative location between the amino acid residues on an -helix can be
measured by two factors, the translation along the helical axis, which is 1.5 Å per two
residues and the turn angle, which is 100o per residue (wiki). Figure 1.11 shows the
relative location of the i, i + 3, i + 4; i, i + 3, i + 7; and i, i + 4, i + 7, when seen from both
the helical axis (a and b) and the side of the -helix (c). Part a) showed the relative
location of the residues when seen from the helical axis. As we can see that the i, i + 3, i
+ 4; i, i + 3, i + 7; and i, i + 4, i + 7 residues are all on one face of the -helix. Part b)
eliminated the -helix backbones, and shows only the relative location among the
residues when seen from the helical axis.

Part c) added the second factor into

consideration – translation along the helical axis, showing their relative location when
seen from the side of the -helix.
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Figure 1.11: Model of the common -helix binding residues
1.7.1

-Helical mimetic scaffolds developed by Hamilton and coworkers
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The success of Hamilton’s 1,4-terphenylene scaffold came from the fact that the
distance between its side chains of the phenyl rings matches that of the i, i + 4, i + 7
(Figure 1.12); while the slightly twisted 1,4-terphenylene scaffold pointed its side chains
to similar side chain orientations of the -helix residues.

Figure 1.12: Comparison of 1,4-terphenylene scaffold with an -helix
The discovery of the 1,4-terphenylene scaffold has removed a lot of successive
work. Figure 1.13 shows the newer scaffolds reported by Hamilton and coworkers (Ernst
et al., 2003); (Davis et al., 2005); (Estroff et al., 2004); (Yin et al., 2005b); (Rodriguez
and Hamilton, 2006); (Kim and Hamilton, 2006). However, none of the newer scaffold
are as potent as the original 1,4-terphenylene one.
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Figure 1.13: Other -helical mimetic scaffolds developed by Hamilton and coworkers
1.7.2

-Helical mimetic scaffolds developed by Rebek and coworkers
The 1,4-terphenylene series of non-peptidic -helical mimetics has not only

inspired the Hamilton group, but also inspired chemists all over the world. Figure 1.14
showed the scaffolds developed by Rebek and coworkers (Volonterio et al., 2007);
(Moisan et al., 2008).
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Figure 1.14: -Helical mimetic scaffolds developed by Rebek and coworkers
1.7.3

Trisubstituted imidazole scaffold
One disadvantage of the 1,4-terphenylene series is that it is very challenging to

synthesize. Antuch and co-workers attempted to solve this problem by modifying the
1,4-terphenylene scaffold to a trisubstituted imidazole (Figure 1.15), which could easily
be synthesized by multicomponent reactions (Antuch et al., 2006).
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Figure 1.15: a) the trisubstituted imidazole scaffolds; b) one molecule from the scaffold
docking into the binding site of the Bad/Bcl-xL
1.7.4

Benzylideneacetophenone scaffold
This scaffold is based on chalcones, which have some intrinsic antitumor

activities. Benzylideneacetophenones are planar molecules that mimic the i, i + 4, i + 7
positions of -helices (Stoll et al., 2001). Figure 1.16 shows the structure of chalcone C
and the way it mimics the -helix.
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Figure 1.16: Structure of chalcone C
1.7.5

trans-Fused polycyclic ethers scaffold
Polycyclic ethers are conceptually inspired by the skeletal feature of marine

toxins. The distance between R1 and R2 group (4.8 Å) is very close to that between i, i +
4 residues (5.4 Å) (Figure 1.17) (Oguri et al., 2005).

Figure 1.17: (Left) trans-Fused polycylic ethers scaffold; (right) its superimposition with
an -helix
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1.8

Synthetic non-peptidic -helical mimetics with other scaffold
We can consider -helices as a linear backbone. There are several reported

potent non-peptidic -helical mimetics that do not have a linear backbone. An example
of this type of mimetic is Nutlin which is the most potent p53/MDM2 antagonist thus far
reported. The problem is that researchers have not developed a general strategy to design
these kinds of -helical mimetic scaffolds.
1.8.1

Nutlins
Nutlins were discovered while screening a diverse library of synthetic chemicals

(Vassilev et al., 2004), of which, nutlin-2 demonstrated IC50 = 140 nM against
p53/MDM2 interactions.

Nutlins represent a design strategy that is different from

Hamilton’s scaffolds, in which all have linear backbones that mimic the coil of an helix. Three of the four substitutions on the imidazoline ring mimic the i, i + 4, i + 7
position of the p53 N-terminal -helix. (Figure 1.18)
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Figure 1.18: a) Structures of the nutlins; b) nutlin-2 superimposing with Phe19, Trp23, and
Leu26 of p53; c) nutlin-2 docking into the binding site of p53/MDM2
1.8.2

1,4-Benzodiazepine-2,5-dione scaffolds
1,4-Benzodiazepine-2,5-diones (Figure 1.19) was also found as a hit when

screening a library (Cummings et al., 2006).

1,4-Benzodiazepine-2,5-diones have a

heterocyclic backbone, which is similar to that of the nutlin molecules.
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Figure 1.19: a) Structures of 1,4-Benzodiazepine-2,5-diones; b) 1,4-Benzodiazepine-2,5diones superimposing with Phe19, Trp23, and Leu26 of p53
1.8.3

Co-activator binding inhibitors

Figure 1.20: Structures of co-activator binding inhibitors
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Co-activator binding inhibitors also contain a heterocyclic backbone (Figure
1.20); they mimic the i, i + 3, i + 4 positions of an -helix (Antuch et al., 2006).
1.9

Summary of non-peptidic -helical mimetics
We have summarized the reported non-peptidic scaffolds that could mimic the -

helices. Both scaffolds with linear backbones and heterocyclic backbones have proven to
be potential -helical mimetics. The idea is that, the backbones should be capable to
assist the hydrophobic side chains to be positioned at the right three-dimensional
location. At present, the linear backbone design is more popular because this design also
mimics the backbone coil of -helix making it more straightforward.
Those molecules showed potential for synthetic scaffolds to mimic the
configuration of three or four critical amino acid residues on a -helix. The challenge
and the joy in designing non-peptidic -helical mimetics are to understand the three
dimensional structures of the molecules.
1.10

Possibility of designing general non-peptidic -helical scaffolds
Most of the reported non-peptidic -helical mimetic molecules were designed to

target one specific protein-protein interaction, such interactions between p53/MDM2,
Bak/Bcl-xL etc. However, as analyzed before (1.3.5), the binding configuration should be
the same, regardless of the amino acid residues. So a question emerged: is it possible to
develop a general non-peptidic -helical scaffold?
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Figure 1.21: Analogs of 1,4-terphenylene scaffold targeting different protein-protein
interactions
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This is how nature accomplishes it, as least. NaIP, p53/MDM2, smMLCK/CaM,
and Rac1/Tiam1 protein-protein interactions all share the i, i + 4, i + 7 binding
configuration (Table 1.1). As a matter of fact, the 1,4-terphenylene backbones have been
used to target several different protein-protein interactions. By replacing the side chains
of the 1,4-terphenylene scaffold, the analogs could be used to target different proteinprotein interactions (Figure 1.21) (Orner et al., 2001); (Ernst et al., 2002); (Kutzki et al.,
2002); (Yin et al., 2005a). This shares the same logic that nature adapted to interact with
different protein-protein interactions – by changing the amino acids residues on the helices.
Although sharing one scaffold, the 1,4-terphenylene scaffold molecules also
showed selectivities between the different protein-protein interactions. For example,
Hamilton and co-workers stated that the 1,4-terphenylene scaffold demonstrated
selectivity between p53/MDM2 and and Bcl-xL by switching between one naphthyl group
(Davis et al., 2007).
1.11

Balance between rational design and combinatorial chemistry
Due to the ease in controlling the well-defined three dimensional surface

configurations of the mimetics, rational design has proven to be a more effective way to
prepare-helical mimetic scaffolds.
One difficulty associated with most of the structurally well-defined scaffolds
developed so far is they are difficult to synthesize. This has become a major factor that
delays chemists from developing more potent -helical mimetics.
25

The strategy used in our research was to modify our target scaffolds so that they
are suitable for combinatorial synthesis. As we were focusing on the rational design and
synthesis of scaffolds with linear backbones, we divided the backbone into several
modules, each of which was corresponding to one of the i, i + 4, i + 7 position side
chains.
In summary, we tried to find a balance between the well-defined configuration
and ease of synthesis by refining our target molecules.
1.12

Cancer: our target
Our goal was to develop -helical mimetic scaffolds that were easy to build, so

that we could synthesize focused libraries rapidly. These libraries should be general for
all protein-protein interactions that involve -helices. However, our group in the Moffitt
Cancer Center, is interested in their anti-cancer properties, specifically, their effects in
apoptosis.
Cancer has been identified as a genetic disease; it is a result of a combination of
deregulated cell proliferation and suppressed apoptosis (Green and Evan, 2002).
1.12.1 Hallmarks of cancer
There are six factors that identify cancer cells from normal diseases (Hanahan and
Weinberg, 2000). First, there is self-sufficiency in the growth signal. Healthy cells need
extracellular growth signals, while cancer cells are capable of generating their own
growth signals. Second, cancer cells are insensitive to anti-growth signals. Antigrowth
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signals in normal cells can temporarily or permanently deactivate the proliferation.
Cancer cells block the antigrowth signals pathways, thus are inert to the signals. Third,
cancer cells evade apoptosis. Apoptosis is defined as programmed cell death. When
DNA damage is sensed, apoptosis will be elicited to kill the damaged cell. Fourth, there
is a limitless replicative potential. Normal cells have a finite replicative potential (60-70
doublings for normal human cell types), while cancer cells do not. The fifth factor that
identifies cancer cells is that there is a sustained angiogenesis. Angiogenesis is the growth
of new blood vessels which are used to supply oxygen and nutrients. This process stops
once a tissue is formed. Cancer cells manage to maintain the constant growth of blood
vessels so that they can continue to grow. Finally, cancer cells have the capability to
invade tissue and metastasize. The primary tumor mass releases cancer cells to colonize
new areas in other parts of the body. This is the cause of about 90% of human cancer
death.
1.12.2 Apoptosis
As stated before, apoptosis is programmed cell death.

Multicellular animals

regularly need to remove excess cells and eliminate damaged cells. Avoiding apoptosis
is essential for the survival of cancer cells.
Apoptosis can be divided into be two processes – sensors and effectors
(Hengartner, 2000). Pro-apoptosis is initiated by the release of cytochrome C, which is
regulated by the Bcl-2 family of proteins. In turn, the Bcl-2 family is, regulated by p53,
which is the tumor suppressor protein.
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When DNA damage is sensed, p53 will be released to upregulate the expression
of Bax. Bax is a proapoptotic protein in Bcl-2 family; which elicits the release of
cytochrome C (Figure 1.22) (SigmaAldrich). This process is called the sensor process.
The released cytochrome C will then activate caspases -8 and/or -9, which are the
enzymes that perform an array of proteolytic processes to kill the cell. This is the
effector process.

Figure 1.22: p53 pathway to elicit apoptosis
1.12.3 p53/MDM2 interaction
p53 is a tumor suppressor protein, which helps maintain the integrity of DNA by
eliciting apoptosis when DNA damage is detected. It has been found that the p53
pathway is lost in most human cancers. There are many ways that cancer cells evade
apoptosis. The most common way is through the mutation of p53, which was detected in
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more than 50% of human cancers (Green and Evan, 2002). For the remaining cases p53
is detected bound to MDM2, causing it to stay in its inactive form.
p53 is regulated by MDM2 by binding to it; but when DNA damage is detected,
p53 should be released to initiate apoptosis. Cancer cells prevent the release of p53 by
amplifying the expression of MDM2 gene, thus producing more of the MDM2 protein. If
the extra MDM2 could be inhibited, the cancer cells with wild-type p53 should be killed.
The MDM2 protein is a small globular protein that has a small hydrophobic cleft
at one face (Figure 1.23 a) (Kussie et al., 1996). This cleft is about 25 Å long, 10 Å at its
widest place, 10 Å at its deepest location. It is formed by four helices constituting the
bottom and the two sides and has two clusters of three-stranded -sheets closing the ends.

Figure 1.23: a) the MDM2 binding cleft; b) crystal structure of p53 binding into the
MDM2 cleft
The p53 binding site is an -helix domain, formed from residues 18 to 26, of
which Phe19 (i), Trp23 (i + 4), and Leu26 (i + 7) are the key binding residues (Figure 1.23
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b). This -helix domain is inserted deeply into the hydrophobic cleft of MDM2, forming
very strong van der Waals interaction with the hydrophobic residues of MDM2.
1.12.4 Bcl-2 family protein-protein interactions
The Bcl-2 protein family plays a central role in regulating apoptosis. The family
contains both pro-apoptotic (Bax, Bak, Bid, Bim) and anti-apoptotic (Bcl-2, Bcl-xL, BclW) functional proteins. Homo- and heterodimerization within the proteins are the key to
modulate their functions; when pro-apoptotic proteins are released from the dimers,
apoptosis will be promoted.

Figure 1.24: Bak binding with the Bcl-xL
The Bcl2 and Bcl-xL proteins contain four Bcl-2 homology (BH) domains (BH1BH4), as well as a C-terminal hydrophobic tail. Bax and Bak contain almost the same
components of Bcl2 and Bcl-xL except for the BH4 domain. Bid and Bik only contain
the BH3 domain.

Among the BH1-BH4 domains, the BH3 domain is involved in
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eliciting the apoptosis process; all Bak, Bax, Bid and Bim share similar BH3 domains
(Green and Evan, 2002).
The binding site between Bcl-xL and Bak were studied by NMR experiments
(Sattler et al., 1997). The binding site of Bak is an -helix domain (Figure 1.24) formed
from residues 72 to 87, of which Val74 (i), Leu78 (i + 4), Ile81 (i + 7) and Ile85 (i + 11) are
the binding residues. This -helix binds to the hydrophobic domain on the surface of the
Bcl-xL, formed by the BH1, BH2, and BH3 domain.
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Chapter Two:
Design and Synthesis of 2,5-Terpyrimidinylenes as More Drug-Like
1,4-Terphenylene Mimetics
2.1

Introduction

2.1.1

Hamilton’s 1,4-Terphenylene Scaffold and Related Work
Hamilton’s 1,4-terphenylene library produced an inhibitor that displays favorable

in vitro activity towards p53/MDM2 heterodimerization (Figure 2.1, a)(Yin et al., 2005a).

Figure 2.1: Hamilton’s most active p53-MDM2 antagonist a and its docking in MDM2
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The 4-, 4’-, and 4’’- positions of this terphenylene scaffold are designed to mimic the i,
i+4, and i+7 sites of an α-helix. The series of molecules bind to the same sites that p53
binds to MDM2; while the side chains occupy the sites that the triad of p53 (F19, W23,
and L26) uses to interact with MDM2.
However, the design has one drawback which prevents it from being a drug
candidate. Both the terphenyl scaffold and the 4-, 4’-, and 4’’- position side chains are
hydrophobic; thus the lipophilicity of this series of molecules is very high (Yin et al.,
2005b).

This is why the 1,4-terphenylene molecules have good bio-activities in

fluorescence polarization (FP) assay, in which the 1,4-terphenylene molecule
competitively replaced the p53 (residues 15–31) in interaction with MDM2 in vitro, but
not in in vivo assay (Yin et al., 2005a). Further investigation on this scaffold was carried
out by the Hamilton group (Ernst et al., 2003), (Davis et al., 2005), (Estroff et al., 2004),
(Yin et al., 2005b), (Rodriguez and Hamilton, 2006), as well as the Rebek’s group
(Moisan et al., 2008), (Volonterio et al., 2007) (Figure 2.2), but they were not as
successful as the original 1,4-terphenylene a (Figure 2.1). Some were designed to mimic
the interaction between Bcl-xL/Bak, but that interaction is also mediated through an helix, therefore the scaffold should show some similar properties.
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Figure 2.2: Recently reported non-peptidic -helical mimetics: Hamilton’s b–f; Rebek’s
g–k
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2.1.2

Design of the 2,5-terpyrimidinylene scaffold
Since none of the newer -helical mimetics are as good as the original 1,4-

terphenylene ones, we hypothesized that the terphenyl scaffold might be the best
antagonist for the p53/MDM interaction. Our group also found that by simply replacing
the phenyl rings of the scaffold with pyrimidine rings, the calculated logP value drops by
an average of 4 (Table 2.1), meaning that the corresponding terpyrimidinylene molecules
are expected to be more water soluble and therefore be more bio-available.
Table 2.1: Calculated logP values for terphenylene and terpyrimidinylene analogs

R0
R0 ’
R1

CN
NH2
i
Bu

CN
Ph
i
Bu

R2

Bn

Bn

Bu
8.6
4.7
3.9

Bu
10.4
5.8
4.6

R3
logP(carbon)
logP(nitrogen)
logP(difference)

i

i

CN
Ph
i
Bu
CH2(1Naph)
i
Bu
11.3
7
4.3

CN
Ph
Bn
CH2(1Naph)
i
Bu
12.2
7.8
4.4

Furthermore, due to the geometrical similarity of phenyl and pyrimidine units
(Figure 2.3), we reasoned that the 2,5-terpyrimidinylene series would have similar
bioactivity, to the corresponding 1,4-terphenylene scaffold.
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Figure 2.3: Geometry of phenyl ring and pyrimidine ring
2.2

Results and Discussion for the 1,4-pyrimidinylene scaffold

2.2.1

Retrosynthesis of the 1,4-pyrimidinylene scaffold
Our group developed a convenient methodology to synthesize pyrimidine rings

with varying side chains (Scheme 2.1).

We condensed commercially available

formamidine/amidine/guanidine m with readily synthesized -unsaturated cyanoketones l at elevated temperatures in the presence of base, making a library of
pyrimidines n with variable 2 and 4 positions.
Scheme 2.1 Synthesis of pyrimidine rings

The -unsaturated -cyanoketones l contains an -cyano group because this
cyano group can potentially be converted into the amidine group after the synthesis of the
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monomer n. The newly generated amidine can react with another molecule of unsaturated -cyanoketone l to form a dimer p. By repeating this process, we planned to
synthesize the trimer o. The corresponding retrosynthetic strategy is shown in Scheme
2.2.
Scheme 2.2: Retrosynthesis of 1,4-terpyrimidinylene

2.2.2

Synthesis of pyrimidine monomer 2.4 library
The synthesis of pyrimidine monomers 2.4a–g is shown in Scheme 2.3.

Acetonitrile was deprotonated by potassium tert-pentoxide, and then reacted with various
esters to produce -cyanoketones 2.2 (Ji et al., 2006), which then reacted with N,Ndimethylformamide dimethyl acetal (DMF-DMA) to form the -unsaturated cyanoketones 2.3 (Reuman et al., 2008).

Most of the ester starting materials are

commercially available; those that are not can be easily prepared from the corresponding
acid by Fisher esterification, using methanol as the solvent, and concentrated sulfuric acid
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Scheme 2.3: Synthesis of the pyrimidine monomers 2.4

Table 2.2: Library of the synthesized pyrimidine monomers 2.4

2.4a
2.4b
2.4c
2.4d
2.4e
2.4f
2.4g
2.4h
2.4i
2.4j

R0
H
H
Me
Ph
Ph
Ph
Ph
NH2
NH2
OMe

R1
Bu
Bn
CH2(1-Naph)
i
Bu
Bn
t
Bu
CH2(1-Naph)
Bn
t
Bu
Bn
t

Yield
71%
39%
60%
60%
87%
83%
40%
91%
75%
30%

as the catalyst. The double bond of compound 2.3 has Z as its dominate configuration;
probably due to the steric hindrance of the carbonyl group. The -unsaturated 42

cyanoketones

2.3

reacted

with

a

variety

of

commercially

available

formamidine/amidines/guanidine to form the pyrimidine monomers 2.4a–g.
This methodology has very broad application, in that a library of monomers have
been synthesized (Table 2.2).
2.2.3

Conversion of the 5-cyano group to an amidine
The key step of the synthesis is the conversion of the 5-cyano to an amidine

group. Several methods have been explored, including the Pinner reaction, the thioPinner reaction (Balo et al., 2007), ammonia in methanol (Balo et al., 2007), and
NaHMDS or LiHMDS (Bruning, 1997) used as nucleophiles, followed by hydrolysis; but
these methods were not successful in yielding the target compounds. Since the 4-alkyl
side chain of our molecules 2.4 (Scheme 2.3) made the cyano group sterically hindered,
all the regular methodologies failed. We eventually found a two-step procedure to
achieve this process (Scheme 2.4) (Judkins et al., 1996). First, free hydroxylamine was
the a nucleophile to attack the cyano group at elevated temperatures to form
amidinoximes q; the N,O single bond was then cleaved in the second step by
Scheme 2.4: Synthetic strategy to convert sterically hindered nitriles to amidines
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hydrogenation to prepare the amidine r.
This hydroxylamine nucleophilic addition reaction is very unique (Scheme 2.4, n
to q), because a great amount of oxygen attacking amide byproduct (yields: 20-50%) was
detected (Scheme 2.5). Typically, the neutral nitrogen atom is a lot more nucleophilic
than the neutral oxygen atom.
Scheme 2.5: Reaction and side reaction of hydroxylamine nucleophilic addition

Exact mechanistic details for this reaction have not been reported. However, a
possible explanation for the diminished selectivity between the N- and O- nucleophilic
species due to the steric hindrance from the ortho substituent on the pyrimidine rings.
It should be pointed out that hydroxylamine behaves not only as a nucleophile,
but also as a cyano activator. In fact, we found that under the same reaction conditions
without hydroxylamine, the cyano group cannot be hydrolyzed to the amide s. Further
evidence in support of hydroxylamine’s properties in this reaction is that, when using Oprotected hydroxylamine, (e.g. O-benzylhydroxylamine and O-methylhydroxylamine),
not even nitrogen attack product q was formed; while all the starting materials remained.
The mechanism proposed by Judkins et al, who originally published the hydroxylamine,
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suggested that the hydrogen atom on the oxygen might behave as a Brønsted acid
interacting with the nitrogen atom of the cyano group, thus activating it through a fivemembered ring transition state (Scheme 2.6).
Scheme 2.6: Proposed transition state of hydroxylamine nucleophilic addition

2.2.4

Synthesis of the pyrimidine dimer
Five pyrimidinylene dimer analogs (Table 2.3) were prepared by condensing the

amidines with the -unsaturated -cyanoketones (Scheme 2.7). The same reaction
Scheme 2.7: Synthesis of the pyrimidine dimer
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conditions which were used to synthesize the pyridine monomers were also used to
synthesize the dimers.

This provides a good example of the broad scope of this

condensation methodology to synthesize the pyrimidine rings.
Table 2.3: Analogs of the synthesized pyrimidine dimers

2.6a
2.6b
2.6c
2.6d
2.6e

2.2.5

R0
Ph
Ph
Ph
Me
Me

R1
Bn
i
Bu
CH2(1-Naph)
CH2(1-Naph)
CH2(1-Naph)

R2
CH2(1-Naph)
CH2(1-Naph)
Bn
Bn
t
Bu

X-Ray crystal structure of a representative dimer
The X-ray diffraction crystal structure of compound 2.6d (Figure 2.4) was

obtained by Dr. Froncezk (Louisiana State University). As it can be seen, the pyrimidine
scaffold is arranged in a twisted conformation.
designed to mimic an -helix.

Figure 2.4 Crystal structure of pyrimidine dimer
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This was expected for compounds

2.2.6

Synthesis of the pyrimidine trimers
Exactly the same process used to synthesize the dimers was also applied to the

synthesis of the pyrimidine trimers (Scheme 2.8). Three trimer analogs were synthesized
(Table 2.4).
Scheme 2.8 Synthesis of the pyrimidine trimers

Table 2.4: Analogs of the synthesized pyrimidine trimers
R0

R1

2.8a

Ph

i

2.8b

Ph

Bn

2.8c

Ph

CH2(1Naph)

Bu
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R2
CH2(1Naph)
CH2(1Naph)
Bn

R3
i

Bu

i

Bu

i

Bu

2.3

Conclusion
We have successfully synthesized several 1,4-terpyrimidinylene analogs. The X-

ray crystal structure did confirm their potential as -helical mimetics.

The newly

synthesized series of molecules has been the one that has the closest structural similarity
to Hamilton’s most active p53/MDM2 inhibitor. However, none of our molecules are
active against p53/MDM2. We reasoned that although they mimic the side chains of
Hamilton’s terphenylene quite well, our molecules are unable to establish the polar
interactions that are available to Hamilton’s molecules due to the polar groups present at
the head and the tail position. Those hydrogen bonding/salt bridge bonding could be
crucial for the molecules’ bioactivities, as well. Another drawback of our molecules is
that they are still too hydrophobic to be suitable drug candidates.

There is an

improvement from Hamilton’s design, but it is still not enough. Third, the synthesis is a
long, linear, time-consuming process; it is very hard to develop a large library of
compounds with such a method.
In summary, we have successfully developed a new series of non-peptidic helical mimetics; however, further improvement is needed for this series of molecules to
be more efficient p53/MDM antagonists, and be sufficiently drug like, cell permeable
compounds.
2.4

Experimental Section

2.4.1

Materials and Methods
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Starting materials, organic and inorganic reagents (ACS grade), and solvents were
obtained from commercial sources and used as received unless otherwise noted.
Moisture- and air-sensitive reactions were carried out under an atmosphere of argon.
Thin layer chromatography (TLC) was performed on glass plates precoated with 0.25
mm thickness of silica gel (60 F-254) with fluorescent indicator (EMD).

Column

chromatographic purification was performed using silica gel 60 Å, #70-230 mesh
(Selecto Scientific). Automated flash chromatography was performed in a FlashMaster II
system (Argonaut-Biotage) using Biotage silica cartridges.

1

H NMR and

13

C NMR

spectra were obtained using a 400 MHz Varian Mercury or 250 MHz Broker plus
instrument at 25 °C in chloroform-d (CDCl3), unless otherwise indicated. Chemical
shifts (ppm) are reported in parts per million (ppm) relative to internal tetramethylsilane
(TMS) or chloroform (ppm 7.26) for 1H NMR and chloroform (ppm 77.0) for 13C NMR.
Multiplicity is expressed as (s = singlet, br s = broad singlet, d = doublet, t = triplet, q =
quartet, or m = multiplet) and the values of coupling constants (J) are given in Hertz
(Hz). High Resolution Mass Spectrometry (HRMS) spectra were carried out on an
Agilent 1100 Series in the ESI-TOF mode. Microwave reactions were performed in a
closed vessel in a Biotage Initiator I microwave reactor. Melting points (uncorrected)
were determined using a Mel-Temp II®, Laboratory Devices, MA, USA.
2.4.2

Experimental Procedures

Methyl 2-(naphthalen-2-yl)acetate (2.1a)
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To a solution of 2-naphthylacetic acid (5.4 mmol) in methanol (10 ml) was added
concentrated sulfuric acid (0.3 mmol). The reaction mixture was stirred under reflux for
3 h. The reaction mixture was concentrated under reduced pressure, and was then
extracted between dichloromethane and water. The organic layer was extracted once
with saturated sodium bicarbonate solution, dried over sodium sulfate, and the solvent
was removed under reduced pressure to afford compound 2.1a as a colorless oil (1.07 g,
100%). 1H NMR (400 MHz, CDCl3) ppm 3.75 (s, 3H), 3.84 (s, 2H), 7.39–7.56 (m, 3H),
7.77 (s, 1H), 7.80–7.90 (m, 3H).

13

C NMR (100 MHz, CDCl3) ppm 41.6, 52.3, 126.07,

126.4, 127.6, 127.9, 127.9, 128.2, 128.5, 131.7, 132.7, 133.7, 172.3.
3-Oxo-4-phenylbutanenitrile (2.2a)

To a solution of methyl phenylacetate (71.0 mmol) and anhydrous acetonitrile (107.2
mmol) in anhydrous THF (20 mL) at 0 ºC in an ice-bath under an argon atmosphere was
added potassium tert-pentoxide (107.2 mmol). The reaction mixture was allowed to
warm up to room temperature and stirred under an argon atmosphere for overnight. A
precipitate was formed within a few minutes (3-5 min.) of stirring and the reaction
mixture remained cloudy until completion. The mixture was filtered and the solid was
washed thoroughly with hexanes.

The filtered residue was then transferred to a
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separatory funnel and was acidified to pH= ~2-3 with saturated aq. potassium bisulfate
solution. DCM was then used to extract the desired compound. The organic layer was
washed with brine, dried over sodium sulfate, and concentrated under reduced pressure to
afford pure 2.2a as a yellow oil (7.34 g, 65%). 1H NMR (400 MHz, CDCl3) ppm 3.46 (s,
2H), 3.86 (s, 2H), 7.21–7.40 (m, 5H).

13

C NMR (100 MHz, CDCl3) ppm 31.1, 49.2,

113.5, 127.9, 129.3, 129.4, 131.9, 195.1.
4-(Naphthalen-1-yl)-3-oxobutanenitrile (2.2b)

Compound 2.2b was prepared following the procedure described for 2.2a. Isolated yield:
64% yield, yellow solid.

1

H NMR (400 MHz, CDCl3) ppm 3.41 (s, 2H), 4.31 (s, 2H),

7.43–7.66 (m, 4H), 7.81–7.98 (m, 3H).

13

C NMR (100 MHz, CDCl3) ppm 31.2, 47.8,

113.7, 123.3, 125.9, 126.6, 127.5, 128.7, 129.0, 129.3, 129.4, 132.0, 134.3, 196.0.
4-(Naphthalen-2-yl)-3-oxobutanenitrile (2.2c)

Compound 2.2c was prepared following the procedure described for 2.2a. Isolated yield:
71% yield, yellow solid.

1

H NMR (400 MHz, CDCl3) ppm 3.51 (s, 2H), 4.06 (s, 2H),

7.34 (dd, J = 1.8, 8.4 Hz, 1H), 7.51–7.57 (m, 2H), 7.74 (s, 1H), 7.84–7.93 (m, 3H).
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13

C

NMR (100 MHz, CDCl3) ppm 31.4, 49.6, 113.8, 126.7, 126.9, 127.1, 127.9, 128.0, 128.8,
129.4, 129.5, 132.9, 133.7, 195.5.
5-Methyl-3-oxohexanenitrile (2.2d)

Compound 2.2d was prepared by the same procedure described for 2.2a. Isolated yield:
73%, yellow oil. 1H NMR (400 MHz, CDCl3) ppm 0.95 (d, J = 0.85 Hz, 3H), 0.97 (d, J
= 0.85 Hz, 3H), 2.11-2.25 (m, 1H), 2.49 (d, J = 6.88 Hz, 2H), 3.43 (s, 2H).

13

C NMR

(100 MHz, CDCl3) ppm 22.5, 24.7, 32. 6, 51.1, 113.9, 197.2.
3-(1H-Indol-3-yl)-3-oxopropanenitrile (2.2e)

Compound 2.2 was prepared following the procedure described by Radwan, M. A. A. et.
al. Isolated yield: 29%, pale orange solid, m.p. 238 oC (lit.= 240 oC). Spectral data is in
agreement with literature (Bioorganic Med. Chem. Lett. 2007, 15, 1206).
2-((Dimethylamino)methylene)-3-oxo-4-phenylbutanenitrile (2.3a)
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To a solution of 2.2a (45.8 mmol) in anhydrous THF (24 mL) was added DMF-DMA
(59.8 mmol). The reaction mixture was stirred at r.t. for overnight. The reaction mixture
was then concentrated under reduced pressure to afford 2.3a as a yellow solid (>90%).
The product was used in the next step without further purification. For characterization
purpose, the product was recrystallized in ethanol to afford light yellow needle-like
crystals, m.p. 134-138 ºC. 1H NMR (400 MHz, CDCl3) ppm 3.20 (s, 3H), 3.38 (s, 3H),
3.95 (s, 2H), 7.21–7.34 (m, 5H), 7.80 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm 9.0,

46.5, 48.2, 120.5, 126.9, 128.7, 129.8, 129.8, 129.9, 135.0, 158.0, 192.9. HRMS (ESI)
calcd. for C13H14N2O [M + H]+ 215.1184, found 215.1194.
2-((Dimethylamino)methylene)-4-(naphthalen-1-yl)-3-oxobutanenitrile (2.3b)

Compound 2.3b was prepared following the procedure described for 2.3a. Isolated yield:
>90%, yellow solid, m.p. 121–122 oC.

1

H NMR (400 MHz, CDCl3) ppm 3.17 (s, 3H),

3.41 (s, 3H), 4.43 (s, 2H), 7.40–7.54 (m, 4H), 7.77 (d, J = 7.9 Hz, 1H), 7.80–7.86 (m,
2H), 7.99 (d, J = 8.2 Hz, 1H).

13

C NMR (100 MHz, CDCl3) ppm 39.1, 44.1, 48.1, 80.1,

120.6, 124.6, 125.7, 125. 8, 126.3, 127.9, 128.7, 128.8, 131.8, 132.6, 134.4, 158.1, 192.6.
HRMS (ESI) calcd. for C17H16N2O [M + H]+ 265.1335, found 265.1313.
2-((Dimethylamino)methylene)-4-(naphthalen-2-yl)-3-oxobutanenitrile (2.3c)

53

Compound 2.3c was prepared following the procedure described for 2.3a. Isolated yield:
>90%, yellow solid. 1H NMR (400 MHz, CDCl3) ppm 3.20 (s, 3H), 3.39 (s, 3H), 4.12 (s,
2H), 7.40–7.50 (m, 3H), 7.77–7.84 (m, 5H).

13

C NMR (100 MHz, CDCl3) ppm 39.0,

46.7, 48.2, 80.1, 120.5, 125.8, 126.2, 127.8, 128.0, 128.0, 128.3, 128.5, 132.6, 133.8,
158.0, 192.9. HRMS (ESI) calcd. for C17H16N2O [M + H]+ 265.1335, found 265.1333.
2-((Dimethylamino)methylene)-5-methyl-3-oxohexanenitrile (2.3d)

Compound 2.3d was prepared following the procedure described for 2.3a. Isolated yield:
>90%, yellow solid. 1H NMR (400 MHz, CDCl3) ppm 0.95 (d, J = 1.48 Hz, 3H), 0.96
(d, J = 1.47 Hz, 3H), 2.13-2.25 (m, 1H), 2.54 (dd, J = 7.03 Hz, 2H), 3.24 (s, 3H), 3.40 (s,
3H), 7.82 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm 22.8, 25.8, 39.0, 48.1, 48.8, 80.8,

120.6, 157.6, 195.4. HRMS (ESI) calcd. for C10H17N2O [M + H]+ 181.1341, found
181.1333.
2-((Dimethylamino)methylene)-4,4-dimethyl-3-oxopentanenitrile (2.3e)
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Compound 2.3e was prepared following the procedure described for 2.3a. Isolated yield:
>90%, white solid, m.p. 48-49 ºC. 1H NMR (400 MHz, CDCl3) ppm 1.32 (s, 9H), 3.23
(s, 2H), 3.42 (s, 2H), 7.92 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm 27.0, 39.1, 43.8,

48.5, 121.5, 160.5, 200.4. HRMS (ESI) calcd. for C10H16N2O [M + H]+ 181.1341, found
181.1340.
4-(tert-Butyl)pyrimidine-5-carbonitrile (2.4a)

To a solution of 2.3e (2.8 mmol) and formamidine acetate salt (16.7 mmol) in anhydrous
ethanol (12 mL) was added sodium ethoxide (16.7 mmol). The reaction mixture was
stirred under reflux for 24 h. The reaction mixture was then concentrated under reduced
pressure. The residue was extracted between DCM and water. The organic layer was
dried over sodium sulfate, and the solvent was removed under reduced pressure to afford
the crude product as a yellow oil. Purification by flash column chromatography on silica
gel (ethyl acetate/hexane, 1:10) affords 2.4b as a colorless oil (0.32 g, 71%).
(400 MHz, CDCl3) ppm 1.52 (s, 9H), 8.90 (s, 1H), 9.24 (s, 1H).
CDCl3) ppm 28.8, 39.9, 107.3, 116.3, 159.4, 162.0, 179.6.
4-Benzylpyrimidine-5-carbonitrile (2.4b)
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13

1

H NMR

C NMR (100 MHz,

Compound 2.4b was prepared following the procedure described for 2.4a. Purification
by flash column chromatography on silica gel (ethyl acetate/hexane, 1:10) affords 2.4b as
a colorless oil (39%). 1H NMR (400 MHz, CDCl3) ppm 4.25 (s, 2H), 7.17–7.26 (m, 2H),
7.26–7.33 (m, 3H), 8.83 (s, 1H), 9.20 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm 43.1,

109.2, 114.8, 127.8, 129.2, 129.5, 135.7, 160.4, 160.5, 172.0. HRMS (ESI) calcd. for
C12H9N3 [M + H]+ 196.0875, found 196.0868.
2-Methyl-4-(naphthalen-1-ylmethyl)pyrimidine-5-carbonitrile (2.4c)

Compound 2.4c was prepared following the procedure described for 2.4a, using
commercially available acetamidine hydrochloride.

Purification by flash column

chromatography on silica gel (ethyl acetate/hexane, 1:4) affords 2.4c as an off-white solid
(60%). 1H NMR (400 MHz, CDCl3) ppm 2.75 (s, 3H), 4.73 (s, 2H), 7.58–7.41 (m, 4H),
7.84 (dd, J = 8.1, 23.5 Hz, 2H), 8.27 (d, J = 8.4 Hz, 1H), 8.80 (s, 1H).

13

C NMR (100

MHz, CDCl3) ppm 26.9, 40.7, 106.2, 115.4, 124.4, 125.7, 126.1, 126.6, 128.6, 128.6,
129.0, 132.1, 132.2, 134.17, 160.6, 171.1, 171.5.
4-iso-Butyl-2-phenylpyrimidine-5-carbonitrile (2.4d)
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Compound 2.4d was prepared following the procedure described for 2.4a, using
commercially available benzamidine hydrochloride.

Purification by flash column

chromatography on silica gel (ethyl acetate/hexane, 1:10) affords 2.4dc as an off-white
solid (60%), m.p. 68-69 ºC. 1H NMR (400 MHz, CDCl3) ppm 1.05 (d, J = 6.7 Hz, 6H),
2.39 (m, 1H), 2.93 (d, J = 7.2 Hz, 2H), 7.49–7.59 (m, 3H), 8.50–8.53 (m, 2H), 8.93 (s,
1H).

13

C NMR (100 MHz, CDCl3) ppm 22.6, 28.9, 45.7, 106.7, 115.8, 129.0, 129.4,

132.4, 136.4, 160.4, 165.7, 173.3. HRMS (ESI) calcd. for C15H15N3 [M + H]+ 238.1344,
found 238.1337.
4-Benzyl-2-phenylpyrimidine-5-carbonitrile (2.4e)

Compound 2.4e was prepared following the procedure described for 2.4a, using
commercially available benzamidine hydrochloride.

Purification by flash column

chromatography on silica gel (ethyl acetate/hexane, 1:7) affords 2.4e as an off-white solid
(87%), m.p. 138-141 ºC. 1H NMR (400 MHz, CDCl3) ppm 4.37 (s, 2H), 7.27–7.30 (m,
1H), 7.35 (dd, J = 10.1, 4.6 Hz, 2H), 7.45–7.59 (m, 5H), 8.49–8.54 (m, 2H), 8.92 (s, 1H).
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13

C NMR (100 MHz, CDCl3) ppm 43.3, 105.9, 115.7, 127.6, 129.0, 129.1, 129.5, 129.5,

132.6, 136.1, 136.2, 160.8, 166.0, 171.9. HRMS (ESI) calcd. for C18H13N3 [M + H]+
272.1188, found 272.1196.
4-tert-Butyl-2-phenylpyrimidine-5-carbonitrile (2.4f)

Compound 2.4f was prepared following the procedure described for 2.4a, using
commercially available benzamidine hydrochloride.

Purification by flash column

chromatography on silica gel (ethyl acetate/hexane, 1:7) affords 2.4f as an off-white solid
(83%), m.p. 101-103 ºC. 1H NMR (400 MHz, CDCl3) ppm 1.60 (s, 9H), 7.49–7.58 (m,
3H), 8.51–8.55 (m, 2H), 8.94 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm 28.8, 40.2,

104.0, 117.2, 128.9, 129.4, 132.4, 136.5, 162.5, 164.8, 179.3. HRMS (ESI) calcd. for
C15H15N3 [M + H]+ 238.1344, found 238.1347.
4-(Naphthalen-1-ylmethyl)-2-phenylpyrimidine-5-carbonitrile (2.4g)
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Compound 2.4g was prepared following the procedure described for 2.4a, using
commercially available benzamidine hydrochloride. Purification by flash column
chromatography on silica gel (ethyl acetate/hexane, 1:7) affords 2.4g as an off-white solid
(40%). 1H NMR (400 MHz, CDCl3) ppm 4.83 (s, 2H), 7.44 – 7.63 (m, 7H), 7.82 (d, J =
8.2, 1H), 7.87 (d, J = 8.1, 1H), 8.37 – 8.45 (m, 3H), 8.94 (s, 1H).

13

C NMR (100 MHz,

CDCl3) ppm 40.7, 106.2, 115.8, 124.7, 125.8, 126.1, 126.5, 128.6, 128.6, 129.0, 129.0,
129.4, 132.6, 161.0, 165.8, 171.6.
2-Amino-4-benzylpyrimidine-5-carbonitrile (2.4h)

Compound 2.4h was prepared following the procedure described for 2.4a, using
commercially available guanidine hydrochloride.

Purification by flash column

chromatography on silica gel (ethyl acetate/hexane, 1:1) affords 2.4h as an off-white
solid (91%), m.p. 129-132 ºC. 1H NMR (400 MHz, CDCl3) ppm 4.10 (s, 2H), 5.58 (br s,
2H), 7.24-7.38 (m, 5H), 8.45 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm 42.9, 97.8,

116.4, 127.5, 129.0, 129.5, 136.0, 162.4, 162.8, 173.5. HRMS (ESI) calcd. for C12H10N4
[M + H]+ 211.0984, found 211.0972.
2-Amino-4-tert-butylpyrimidine-5-carbonitrile (2.4i)
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Compound 2.4i was prepared following the procedure described for 2.4a, using
commercially available guanidine hydrochloride.

Purification by flash column

chromatography on silica gel (ethyl acetate/hexane, 1:1) affords 2.4i as an off-white solid
(75%), m.p. 89-91 ºC.
8.44 (s, 1H).

13

1

H NMR (400 MHz, CDCl3) ppm 1.43 (s, 9H), 5.56 (br s, 2H),

C NMR (100 MHz, CDCl3) ppm 28.5, 39.5, 95.6, 118.3, 162.4, 164.0,

181.2. HRMS (ESI) calcd. for C9H12N4 [M + H]+ 177.1140, found 177.1148.
4-Benzyl-2-methoxypyrimidine-5-carbonitrile (2.4j)

Compound 2.4j was prepared following the procedure described for 2.4a, using
commercially available O-methylisourea sulfate.

Purification by flash column

chromatography on silica gel (ethyl acetate/hexane, 1:3) affords 2.4j as an off-white solid
(30%). 1H NMR (400 MHz, CDCl3) ppm 4.07 (s, 3H), 4.22 (s, 2H), 7.26 (t, J = 7.3 Hz,
1H), 7.29 – 7.35 (m, 2H), 7.41 (d, J = 7.4 Hz, 2H), 8.68 (s, 1H).

13

C NMR (100 MHz,

CDCl3) ppm 43.1, 56.1, 101.9, 115.5, 127.7, 129.1, 129.5, 135.8, 163.4, 166.2, 175.1.
4'-Benzyl-4-(naphthalen-1-ylmethyl)-2'-phenyl-[2,5'-bipyrimidine]-5-carbonitrile
(2.6a)
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Step 1: To a solution of compound 2.4e (4.1 mmol) in ethanol (9 mL) was added a
solution of hydroxylamine hydrochloride (16.3 mmol) and potassium carbonate (8.1
mmol) in water (5 mL). The reaction mixture was stirred under reflux overnight. The
reaction mixture was concentrated under reduced pressure. The residue was extracted
between DCM and water. The organic layer was dried over sodium sulfate, and the
solvent was removed under reduced pressure to obtain the intermediate amidoxime,
which was used in the next step without further purification.
Step 2: To a solution of the intermediate from step 1 in glacial acetic acid (10 mL) was
added acetic anhydride (246 µL). After 5 min. of stirring, a solution of potassium
formate prepared in situ from potassium carbonate (10 mmol) and formic acid (20 mmol)
in methanol (4 mL) was added, followed by 10% Pd/C (0.4 mmol). The reaction mixture
was stirred at room temperature overnight. The reaction mixture was filtered through
CeliteTM and rinsed with methanol. The filtrate was concentrated under reduced pressure
to afford a yellow residue. This residue was redissolved in DCM and filtered through the
CeliteTM and rinsed with DCM. The filtrate was concentrated under reduced pressure to
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afford the crude the carboxamidine acetate salt as a yellow solid, which was used in the
next step without further purification.
Step 3: To the solution of the carboxamidine salt from step 2 in ethanol (5 mL) was
added compound 2.3d (4.1 mmol) and sodium ethoxide (4.1 mmol).
mixture was stirred under reflux for overnight.

The reaction

The reaction mixture was then

concentrated under reduced pressure. The residue was extracted between DCM and
water. The organic layer was dried over sodium sulfate, and the solvent was removed by
reduced pressure to afford the crude product as a yellow solid. Purification by flash
column chromatography on silica gel (ethyl acetate/hexane, 1:5) affords 2.4b as white
solid (32%), m.p. 165– 166 oC. 1H NMR (400 MHz, CDCl3) ppm 4.45 (s, 2H), 4.84 (s,
2H), 6.88–6.95 (m, 2H), 7.06–7.11 (m, 3H), 7.42–7.56 (m, 7H), 7.84 (dd, J = 8.1, 19.3
Hz, 2H), 8.17 (d, J = 8.2 Hz, 1H), 8.45–8.52 (m, 2H), 9.01 (s, 1H), 9.33 (s, 1H).

13

C

NMR (100 MHz, CDCl3) ppm 40.1, 43.2, 105.0, 106.3, 115.1, 124.3, 125.5, 125.9, 126.2,
126.5, 127.3, 127.4, 127.7, 128.8, 128.9, 129.0, 129.1, 129.4, 131.6, 132.4, 134.0, 135.1,
135.6, 137.0, 160.3, 160.6, 165.1, 169.1, 172.1. HRMS (ESI) calcd. for C33H22N5 [M +
H]+ 490.2026, found 490.2002.
4'-iso-Butyl-4-(naphthalen-1-ylmethyl)-2'-phenyl-[2,5'-bipyrimidine]-5-carbonitrile
(2.6b)
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Compound 2.6b was prepared following the procedure described for 2.6a using 2.4d.
Purification by flash column chromatography on silica gel (ethyl acetate/hexane, 1:10)
affords 2.6c as an off-white solid (33%).
4-Benzyl-4'-(naphthalen-1-ylmethyl)-2'-phenyl-[2,5'-bipyrimidine]-5-carbonitrile
(2.6c)

Compound 2.6c was prepared following the procedure described for 2.6a using 2.4g.
Purification by flash column chromatography on silica gel (ethyl acetate/hexane, 1:10)
affords 2.6c as an off-white solid (41%). 1H NMR (400 MHz, CDCl3) ppm 4.15 (s, 2H),
5.17 (s, 2H), 6.96 (d, J = 7.1 Hz, 1H), 7.21 (d, J = 1.9 Hz, 4H), 7.40–7.53 (m, 5H), 7.71
(d, J = 8.2 Hz, 1H), 7.83–7.88 (m, 1H), 8.10–8.15 (m, 1H), 8.39 (ddd, J = 6.8, 3.8, 2.0
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Hz, 2H), 8.87 (s, 1H), 9.52 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm 40.0, 43.2, 106.3,

115.1, 124.3, 125.5, 125.8, 126.2, 126.6, 127.3, 127.4, 127.7, 128.8, 129.9, 129.4, 160.3,
160.6, 165.1, 160.6, 165.1, 169.1, 172.1.
4-Benzyl-2'-methyl-4'-(naphthalen-1-ylmethyl)-[2,5'-bipyrimidine]-5-carbonitrile
(2.6d)

Compound 2.6d was prepared following the procedure described for 2.6a using 2.4c.
Purification by flash column chromatography on silica gel (ethyl acetate/hexane, 1:10)
affords 2.6d as an off-white solid (30%). 1H NMR (400 MHz, CDCl3) ppm 2.81 (s, 3H),
4.04 (s, 2H), 5.08 (s, 2H), 6.76 (d, J = 7.10 Hz, 1H), 7.06-7.11 (m, 2H), 7.14-7.23 (m,
4H), 7.45-7.53 (m, 2H), 7.66 (d, J = 8.21 Hz, 1H), 7.81 (d, J = 8.26 Hz, 1H), 8.06 (d, J =
7.73 Hz, 1H), 8.77 (s, 1H), 9.36 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm 26.3, 39.7,

43.1, 106.5, 115.0, 123.9, 125.5, 126.0, 126.1, 126.3, 127.3, 127.5, 127.7, 129.0, 129.1,
129.4, 132.2, 133.9, 134.9, 135.6, 159.7, 160.6, 164.9, 169.0, 169.6, 172.0.
4-(tert-Butyl)-2'-methyl-4'-(naphthalen-1-ylmethyl)-[2,5'-bipyrimidine]-5carbonitrile (2.6e)
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Compound 2.6d was prepared following the procedure described for 2.6a using 2.4c.
Purification by flash column chromatography on silica gel (ethyl acetate/hexane, 1:10)
affords 2.6d as an off-white solid (30%). 1H NMR (400 MHz, CDCl3) ppm 1.35 (s, 9H),
2.77 (s, 3H), 5.11 (s, 2H), 6.80 (d, J = 7.1 Hz, 1H), 7.20 (d, J = 7.2 Hz, 1H), 7.43–7.51
(m, 2H), 7.64 (d, J = 8.3 Hz, 1H), 7.78–7.83 (m, 1H), 8.02 (d, J = 9.0 Hz, 1H), 8.80 (s,
1H), 9.32 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm 14.4，21.3, 26.4, 28.6, 29.9, 39.7,

40.1, 60.6, 104.6, 116.4, 124.0, 125.4, 125.9, 126.2, 126.2, 127.3, 127.8, 128.9, 132.2,
133.9, 134.7, 159.7, 162.2, 164.1, 168.6, 169.5, 171.3, 179.6.
5”-Cyano-4,4”-diisobutyl-4’-(1-naphthylmethyl)-2-phenylterpyrimidine (2.8a)
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Compound 2.8a was prepared following the procedure described for 2.6a using 2.6b.
Purification by flash column chromatography on silica gel (ethyl acetate/hexane, 1:10)
affords 2.8a as an off-white solid (20%). 1H NMR (400 MHz, CDCl3) ppm 0.71 (d, J =
6.7 Hz, 6H), 0.76 (d, J = 6.6 Hz, 6H), 1.89–2.01 (m, 1H), 2.05-2.18 (m, 1H), 2.66 (d, J =
7.3 Hz, 2H), 2.95 (d, J = 7.0 Hz, 2H), 5.14 (s, 2H), 6.95 (d, J = 7.0 Hz, 1H), 7.19-7.25
(m, 1H), 7.39-7.47 (m, 5H), 7.65 (d, J = 8.2 Hz, 1H), 7.79 (dd, J = 6.2, 3.3 Hz, 1H), 7.98
(dd, J = 6.1, 3.4 Hz, 1H), 8.41-8.48 (m, 2H), 8.86 (s, 1H), 9.21 (s, 1H), 9.53 (s, 1H).

13

C

NMR (100 MHz, CDCl3) ppm 22.4, 22.7, 28.4, 29.0, 40.1, 44.5, 45.6, 107.5, 115.0,
124.0, 125.5, 126.0, 126.4, 126.7, 127.5, 127.7, 128.5, 128.8, 128.8, 129.1, 131.1, 132.3,
134.1, 134.7, 137.8, 159.5, 160.0, 160.2, 164.1, 164.5, 164.9, 169.1, 170.0, 173.8. HRMS
(ESI) calcd. for C38H35N7 [M + H]+ 590.3027, found 590.2984.
5”-Cyano-4”-isobutyl-4’-(1-naphthylmethyl)-4-(2-phenylmethyl)-2phenylterpyrimidine (2.8b):
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Compound 2.8a was prepared following the procedure described for 2.6a using 2.6b.
Purification by flash column chromatography on silica gel (ethyl acetate/hexane, 1:10)
affords 2.8b as an off-white solid (20%). 1H NMR (400 MHz, CDCl3) ppm 0.71 (d, J =
6.7 Hz, 6H), 0.76 (d, J = 6.6 Hz, 6H), 1.89–2.01 (m, 1H), 2.05-2.18 (m, 1H), 2.66 (d, J =
7.3 Hz, 2H), 2.95 (d, J = 7.0 Hz, 2H), 5.14 (s, 2H), 6.95 (d, J = 7.0 Hz, 1H), 7.19-7.25
(m, 1H), 7.39-7.47 (m, 5H), 7.65 (d, J = 8.2 Hz, 1H), 7.79 (dd, J = 6.2, 3.3 Hz, 1H), 7.98
(dd, J = 6.1, 3.4 Hz, 1H), 8.41-8.48 (m, 2H), 8.86 (s, 1H), 9.21 (s, 1H), 9.53 (s, 1H).

13

C

NMR (100 MHz, CDCl3) ppm 22.4, 22.7, 28.4, 29.0, 40.1, 44.5, 45.6, 107.5, 115.0,
124.0, 125.5, 126.0, 126.4, 126.7, 127.5, 127.7, 128.5, 128.8, 128.8, 129.1, 131.1, 132.3,
134.1, 134.7, 137.8, 159.5, 160.0, 160.2, 164.1, 164.5, 164.9, 169.1, 170.0, 173.8. HRMS
(ESI) calcd. for C38H35N7 [M + H]+ 590.3027, found 590.2984.
5”-Cyano-4”-isobutyl-4’-(2-phenylmethyl)-4-(1-naphthylmethyl)-2phenylterpyrimidine (2.8C):
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Compound 2.8c was prepared following the procedure described for 2.6a using 2.6c.
Purification by flash column chromatography on silica gel (ethyl acetate/hexane, 1:10)
affords 2.8c as an off-white solid (17%). 1H NMR (400 MHz, CDCl3) ppm 0.93 (d, J =
6.6 Hz, 6H), 2.13 – 2.27 (m, 1H), 2.85 (d, J = 7.2 Hz, 2H), 4.55 (s, 2H), 5.10 (s, 2H),
6.94 - 7.08 (m, 5H), 7.21 (t, J = 7.6 Hz, 1H), 7.29 - 7.40 (m, 6H), 7.62 (d, J = 8.2 Hz,
1H), 7.75 (dd, J = 6.2, 3.3 Hz, 1H), 8.06 (dd, J = 5.9, 3.4 Hz, 1H), 8.23 - 8.28 (m, 2H),
8.92 (d, J = 0.5 Hz, 1H), 9.38 (d, J = 0.5 Hz, 1H), 9.44 (d, J = 0.5 Hz, 1H).

13

C NMR

(100 MHz, CDCl3) ppm 22.6, 29.2, 39.7, 42.2, 45.8, 107.6, 115.0, 124.8, 125.6, 125.6,
126.0, 126.7, 127.0, 127.2, 127.5, 128.2, 128.6, 128.7, 128.7, 128.9, 129.3, 131.2, 132.7,
134.0, 135.5, 137.4, 138.1, 159.9, 160.1, 160.2, 164.2, 164.5, 164.5, 168.6, 169.1, 173.7.
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Chapter Three:
Convergent Approach to Synthesis 2,5-Terpyrimidinylene Based Derivatives
3.1

Introduction

3.1.1

Optimization of synthetic route to the 2,5-terpyrimidinylene scaffold
We have successfully synthesized several analogs of the 2,5-terpyrimidinylene

scaffold; however, the design and the synthesis need further optimizations.
3.1.2

Modifications that might lead to improvement of the bioactivities

Figure 3.1: Examples of Hamilton’s 1,4-terphenylene derivatives
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Figure 3.2: Synthesized 2,5-terpyrimidinylene derivatives
Our strategy focused on the synthesis of novel analogs of Hamilton’s 1,4terphenylene derivatives (Figure 3.1); however, the 2,5-terpyrimidinylene analogs
(Figure 3.2) that we have synthesized did not show any activities against p53/MDM2.

Figure 3.3: Structure comparison of 1,4-terphenylene and 2,5-pyrimidinylene scaffold
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We proposed the following two reasons. First, comparison of our synthesized
molecules with Hamilton’s terphenylene scaffold (Figure 3.3) show that, even though the
side chains of our molecules mimic the side chains of his 1,4-terphenylene derivatives,
our molecules lack of the hydrogen bonding / salt bridge potential that feature at the
extreme terminals in Hamilton’s molecules.
From Hamilton’s first report of the 1,4-terphenylene derivatives (Orner et al.,
2001) which were used to target the interaction between calmodulin (CaM) and an Rhelical domain of smooth muscle myosin light-chain kinase (smMLCK); to Hamilton’s
later use of these derivatives to target the interaction between p53 and MDM2 (Yin et al.,
2005), Hamilton’s group have tested the importance of the terminal carboxylic acid
groups. In all cases, molecules without the terminal carboxylic acid groups did not show
bio-activities. Our 2,5-terpyrimidinylene scaffold has a phenyl group, and a cyano group
at the terminal positions, which cannot be involved in hydrogen bonding / salt bridge
interactions at physiology pH. This lack of interaction might be one of the major reasons
why our molecules did not show bioactivity.

We attempted to mimic the terminal

carboxyl acid groups of Hamilton’s molecules, but for the synthetic methodology that we
have developed, it was very challenging. We were also trying to hydrolyze the 5’’-cyano
group to carboxylic acid, but because of the high steric hindrance of the 5-position, and
the high hydrophobicity of the 2,5-terpyrimidinylene derivative, the hydrolysis was very
challenging.
Furthermore, we suggest that more hydrophilic elements be added to our
molecules. The solubility of our molecules in DMSO was not as good as we planned.
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3.1.3

Problems existing in the developed synthetic process
It is difficult to make a library of molecules using the most recent synthesis

process that has been developed because it is a long and tedious process. This procedure
is a linear synthesis, containing 9 steps, almost all of which required at least 12 h reaction
time. Typically, it took over a week to make one analog.
Scheme 3.1: Reaction and side reaction of hydroxylamine nucleophilic addition

Additionally, the overall yield is very low, normally about 1-2%. The low yield
of the overall synthesis was the result of two reactions. The first is the hydroxylamine
nucleophilic addition reaction, which generally produces 20-50% side product amide b
(Scheme 3.1). The second yield limiting reaction is the condensation reaction to form the
pyrimidine ring (Scheme 3.2). This reaction generates water in situ, which hydrolyzed
Scheme 3.2: Reaction and side reaction of amidine condensation reaction
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the limiting reagent amidine d to amide f; this side product is confirmed by proton NMR.
This may be the reason why we never had a yield greater than 50% when we did the
condensation reaction to make the pyrimidine dimers and trimers. Unfortunately, both of
these reactions need to be carried out twice during the overall synthesis, which made the
overall yield of the synthesis low.
To simplify the synthesis process, we choose to make our 2,5-terpyrimidine
molecules with a phenyl group at the 2-position. We could very well use more diverse
groups, e.g. –NH2, etc., but that would increase the difficulty of synthesis even more.
3.1.4

Convergent synthetic strategy
To improve the yield of the synthesis, and to reduce the synthesis time, we chose

to use a convergent strategy (Scheme 3.3) instead of the linear synthesis. Retrosynthetic
analysis revealed that the target molecule g could be derived from the amidine h and the
Scheme 3.3: Retrosynthesis using the convergent strategy
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-unsaturated -pyrimidineketone i. The synthesis of amidine h has been previously
reported; so we focused our attention on exploring the synthesis of -unsaturated pyrimidineketone i.
A convergent synthetic approach presents several advantages. First, the amidine
h and the -unsaturated -pyrimidineketones i can be simultaneously synthesized,
reducing the overall synthesis time. Second, the synthesis of several analogs h and i
would allow us to easily achieve the diversity of the library of the target molecules.
Last but not least, since the top amidine half h would be easily made, we can use
more than 1 equiv. of the amidine h in the last condensation step to increase overall yield.
3.2

Results and Discussion for the synthesis of the newunsaturated ketones

3.2.1

Retrosynthetic to make the -unsaturated -pyrimidineketones
The synthesis of the fragment i (Scheme 3.4) relied on our well-developed

reaction: -substituted ketone j reacting with DMF-DMA. The -pyrimidine ketone j, in
turn, could be made by condensation of -amidine ketone k with another -unsaturated
Scheme 3.4: Retrosynthesis of the -unsaturated -pyrimidineketones
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-cyanoketone (Scheme 3.2 c). And the -amidine ketone k could be prepared using our
extensive collection of -cyano ketone l.
3.2.2

Attempted synthesis of the -unsaturated -pyrimidineketones 3.5
With this in mind, the following steps have been carried out (Scheme 3.5).

Containing a good electronphilic ketone group, starting material 3.1 was protected to
prevent the side reactions. We decided to protect the ketone group by reducing it to
alcohol, because the alcohol group should be inert to the following reaction conditions,
which contain both acidic and basic conditions. Reduction of the starting material cyano ketone 3.1 using sodium borohydride at 0 ºC gave the -cyano alcohol 3.2 in
excellent yield. To convert cyano group 3.2 to amidine 3.3, we relied on the
Scheme 3.5: Attempted synthesis of compound 3.5
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hydroxylamine reaction. Nucleophilic addition of hydroxylamine to compound 3.2 at
high temperature gave the amidoxime 3.3 in very good yield. It is worth to point out that,
in this reaction (Scheme 3.6), no amide side product was observed. This shows the
influence of the steric hindrance in this reaction: if the cyano group is not hindered, only
the nitrogen atom of the hydroxylamine behaves as the nucleophile. After this reaction,
hydrogenation of the amidoxine 3.3 gave the amidine intermediate, which condensed
with an -unsaturated -cyanoketone 2.3d to give the -pyrimidine alcohol 3.4.
However, at this stage, we could not oxidize the 2o alcohol 3.4 to the ketone 3.5. We
tried Jones oxidation (Zibuck and Streiber, 1993), Swern oxidation (Dondoni and
Perrone, 2000), Dess-Martin oxidation (Sniady et al., 2007), and PCC (Tu et al., 2003).
However, only the Dess-Martin oxidation gave a trace mount of product, no product
could be detected in the other oxidation methods. Based on the results, no starting
material alcohol could be recycled after all these oxidation methods. We reasoned that
the pyrimidine ring is not stable under those oxidation conditions.
Scheme 3.6: Hydroxylamine addition of compound 3.2

3.2.3

Attempted synthesis of -unsaturated ketones using 1,2,3-triazole ring
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Some new results from our group showed that, besides the six-membered ring, the
five-membered ring could also be used in the scaffold while retaining the -helical
mimetic properties.

Therefore, we modified our target molecules by replacing the

pyrimidine ring with the 1,2,3-triazole ring (the detailed reason will be discussed in
Chapter 4). The synthetic strategy remained unvaried (Scheme 3.7); the 1,2,3-triazole
ring could be prepared using the azide alkyne Huisgen cycloaddition, also known as click
chemistry.
Scheme 3.7: Synthesis of the -unsaturated -triazoleketones
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First, a simple bromination reaction at the -position of the ketone gave the bromine ketone 3.6. This method is not as general as the ―acid chloride–CH2N2–HBr‖
strategy, but it is a simple one step high yielding reaction, perfect for the trial series.
Then, azide behaved as a nucleophile to undergo a SN2 reaction to kick out the bromide
as a leaving group.

The resulting azide 3.7 underwent an azide alkyne Huisgen

cycloaddition to form the -triazole ketone 3.8 (Chen et al., 2007). This -triazole
ketone 3.8 reacted with DMF-DMA at room temperature resulting in compound 3.9, an
analog of the -unsaturated ketone i in Scheme 3.3. To check the reactivity of this
series of -unsaturated -triazoleketones, 3.9 was used to condense with guanidine. As
expected, a pyrimidine ring was formed, getting an 80% yield in the cyclization reaction.
Scheme 3.8: Condensation to synthesize the hybrid trimer 3.11
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After the proof of the reactivity of the -unsaturated -triazoleketones we
condensed 3.9 with an amidine monomer 2.5d to make a hybrid pyrimidine-triazole
trimer molecule 3.11 (Scheme 3.8).
3.2.4

Biological testing of 3.10
Compound 3.10 was tested in FP assay against p53/MDMx interaction, in which

it showed 6 ± 17% activities at 100 L. Considering 3.10 is a dimer molecule which has
a molecular weight of only 324.38, this scaffold showed the potential to be an antagonist
of p53/MDMx interaction.
3.3

Conclusion
We have successfully developed a convergent route to synthesize a new

generation of non-peptidic -helix mimetics. The newer generation of the molecules has
more hydrogen bonding/ionic bonding potentials at the top and bottom positions, while
retaining the hydrophobic side chains that mimic the side chains of the -helical
mimetics. The synthesis of this new generation of trimers has been simplified from the
2,5-terpyrimidinylene generation; it contains 7 steps from the longest route, and most of
those reactions are high yielding. This strategy is more conductive in synthesizing a
library of molecules.
3.4

Experimental Procedures

3-Hydroxy-4-phenylbutanenitrile (3.2)
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To a solution of 2.2a (0.47 mmol) in methanol (2 ml) cooled to 0 ºC in an ice-bath was
added sodium borohydride (0.73 mmol). The reaction mixture was stirred at 0 ºC for 1.5
h. After the reaction, aq. H2SO4 (1 M) was added to the reaction mixture until pH = 6.
The mixture was then concentrated under reduced pressure. The residue was extracted
with ethyl acetate 3 times. The combined organic layer was extracted once with brine
solution, dried over sodium sulfate, and the solvent was removed under reduced pressure
to afford the crude product as yellow solid. Purification by flash column chromatography
on silica gel (ethyl acetate/hexane, 1:2) to afford 3.2 as a white solid (70 mg, 92%).

1

H

NMR (400 MHz, CDCl3) ppm 2.50 (qd, J = 16.7, 5.5 Hz, 2H), 2.69 (bs, 1H), 2.88 (d, J =
6.7 Hz, 2H), 4.07–4.18 (m, 1H), 7.19–7.37 (m, 5H).

13

C NMR (100 MHz, CDCl3) ppm

25.3, 43.0, 68.8, 117.9, 127.4, 129.1, 129.6, 136.6.
N',3-Dihydroxy-4-phenylbutanimidamide acetate (3.3)

To a solution of compound 3.2 (3.9 mmol) in ethanol (11 mL) was added a solution of
hydroxylamine hydrochloride (19.7 mmol) and potassium carbonate (9.8 mmol) in water
(4 mL). The reaction mixture was stirred under reflux for 14 h. The reaction mixture
was concentrated under reduced pressure. The residue was extracted between DCM and
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water. The organic layer was dried over sodium sulfate, and the solvent was removed
under reduced pressure to afford the crude product as yellow solid. Purification by flash
column chromatography on silica gel (methanol/ethyl acetate, 1:20) affords the
amidoxime 3.3 as a white solid (0.45 g, 59%).

1

H NMR (400 MHz, CDCl3) ppm 2.14–

2.40 (m, 2H), 2.69–2.78 (m, 2H), 4.00–4.10 (m, 1H), 4.80–5.30 (br m, 4H), 7.13–7.32
(m, 5H).

13

C NMR (100 MHz, CDCl3) ppm 37.8, 43.7, 70.7, 126.8, 128.8, 128.8, 129.7,

138.2. HRMS (ESI) calcd. for C10H14N2O2 [M + H]+ 195.1128, found 195.1203.
2-(2-Hydroxy-3-phenylpropyl)-4-isobutylpyrimidine-5-carbonitrile (3.4)

Step 1: To a solution of the 3.3 (1.5 mmol) in glacial acetic acid (3 mL) was added acetic
anhydride (175 µL). After 5 min. of stirring, a solution of potassium formate prepared in
situ from potassium carbonate (5 mmol) and formic acid (10 mmol) in methanol (2 mL)
was added followed by 10% Pd/C (0.2 mmol). The reaction mixture was stirred at room
temperature for 2 h. The reaction mixture was filtered through CeliteTM and rinsed with
methanol.

The filtrate was concentrated under reduced pressure to afford a yellow

residue. This residue was redissolved in DCM and filtered through CeliteTM and rinsed
with DCM. The filtrate was concentrated under reduced pressure to afford the crude
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amidine acetate salt as a yellow solid, which was used in the next step without further
purification.
Step 2: To the solution of the amidine salt (0.8 mmol) from step 2 in ethanol (3 mL) was
added compound 2.3d (0.8 mmol) and triethylamine (1.6 mmol). The reaction mixture
was stirred under reflux for overnight. The reaction mixture was then concentrated under
reduced pressure. The residue was extracted between DCM and water. The organic layer
was dried over sodium sulfate, and the solvent was removed by reduced pressure to
afford the crude product as a yellow solid. Purification by flash column chromatography
on silica gel (ethyl acetate/hexane, 1:2) afforded 3.4 as white solid (32%). 1H NMR (400
MHz, CDCl3) ppm 0.98 (d, J = 6.7 Hz, 6H), 2.23 (tt, J = 13.7, 6.9 Hz, 1H), 2.84 (d, J =
7.3 Hz, 2H), 2.90 (dd, J = 15.9, 5.9 Hz, 1H), 2.98 (d, J = 7.0 Hz, 1H), 3.12 (dd, J = 16.3,
9.0 Hz, 1H), 3.23 (dd, J = 16.3, 2.9 Hz, 1H), 3.97 ( br s, 1H), 4.43 (d, J = 8.3 Hz, 1H),
7.20–7.36 (m, 5H), 8.80 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm 22.5, 22.5, 29.2,

43.5, 45.2, 45.6, 70.9, 107.2, 115.1, 126.8, 128.8, 129.8, 138.1, 160.0, 171.8, 173.2
2-Bromo-1-phenylethanone (3.6)

To an ice cooled solution of acetophenone (1.7 mmol) and catalytic amount of aluminum
chloride in diethyl ether (4 ml) was added bromine (4.3 mmol). The reaction mixture
was stirred at 0 ºC until the red color faded. After the reaction, aq. H 2SO4 (1 M) was
added to the reaction mixture until pH = 6. The mixture was then concentrated under
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reduced pressure. The residue was extracted with ethyl acetate 3 times. The combined
organic layer was extracted once with brine solution, dried over sodium sulfate, and the
solvent was removed under reduced pressure to afford the crude product as a yellow
solid. Purification by flash column chromatography on silica gel (ethyl acetate/hexane,
1:2) affords 3.6 as a white solid (70 mg, 92%).

1

H NMR (400 MHz, CDCl3) ppm 2.50

(qd, J = 16.7, 5.5 Hz, 2H), 2.69 (bs, 1H), 2.88 (d, J = 6.7 Hz, 2H), 4.07–4.18 (m, 1H),
7.19–7.37 (m, 5H).
2-Azido-1-phenylethanone (3.7)

Sodium azide (4.3 mmol) was dissolved in DMSO (9 mL) and the solution was stirred for
12 h. To this solution was added 3.6 (2.2 mmol). The reaction mixture was stirred at
room temperature for 4 h. The reaction mixture was then concentrated under reduced
pressure using the Biotage V10. The residue was extracted between DCM and water.
The organic layer was dried over sodium sulfate, and the solvent was removed under
reduced pressure to afford the crude product as yellow oil. Purification by flash column
chromatography on silica gel (ethyl acetate/hexane, 1:7) affords the 3.7 as a colorless oil
(0.15 g, 59%).

1

H NMR (400 MHz, CDCl3) ppm 4.56 (s, 2H), 7.46–7.54 (m, 2H), 7.59–

7.66 (m, 1H), 7.88–7.92 (m, 2H).
2-(4-(1-Hydroxy-3-methylbutyl)-1H-1,2,3-triazol-1-yl)-1-phenylethanone (3.8)
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To a solution of 3.7 (0.29 mmol) and 5-methyl-1-hexyn-3-ol (0.29 mmol) in tert-butanol
(4 mL) was added a solution of (+)-sodium L-ascorbate (0.29 mmol) in water (2 mL) and
copper(II) sulfate pentahydrate (0.14 mmol) in water (2 mL), respectively. The reaction
mixture was stirred at room temperature for 24 h. The mixture was then concentrated
under reduced pressure. The residue was extracted between ethyl acetate and water. The
combined organic layer was extracted once with brine solution, dried over sodium
sulfate, and the solvent was removed under reduced pressure to afford the crude product
as a yellow solid. Purification by flash column chromatography on silica gel (ethyl
acetate/hexane, 2:1) affords 3.8 as a white solid (63 mg, 79%).

1

H NMR (400 MHz,

CDCl3) ppm 0.93 (d, J = 6.3 Hz, 6H), 1.67 (ddd, J = 4.2, 9.1, 13.3 Hz, 1H), 1.81 (qd, J =
6.1, 13.2 Hz, 2H), 3.36 (br s, 1H), 4.95 (dd, J = 5.0, 8.5 Hz, 1H), 5.81 (s, 2H), 7.49 (dd, J
= 4.8, 10.7 Hz, 2H), 7.60 (s, 1H), 7.63 (t, J = 7.5 Hz, 1H), 7.94 (dd, J = 1.1, 8.3 Hz, 2H).
13

C NMR (100 MHz, CDCl3) ppm 22.2, 23.4, 24.7, 46.4, 55.7, 65.3, 122.8, 128.4, 129.4,

134.1, 134.8, 152.5, 190.8. HRMS (ESI) calcd. for C15H19N3O2 [M + H]+ 274.1550,
found 274.1557.
3-(Dimethylamino)-2-(4-(1-hydroxy-3-methylbutyl)-1H-1,2,3-triazol-1-yl)-1phenylprop-2-en-1-one (3.9)
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To a solution of 3.8 (1.6 mmol) in THF (24 ml) under argon atmosphere was added
DMF-DMA (4.3 mmol). The reaction mixture was stirred overnight. The reaction
mixture was concentrated under reduced pressure affords the crude product as brown
solid. Purification by flash column chromatography on silica gel (methanol/ethyl acetate,
1:20) afforded 3.9 as a white solid (0.42 g, 82%).

1

H NMR (400 MHz, CDCl3) ppm

0.90 (dd, J = 6.2, 2.8 Hz, 6H), 1.55—1.80 (m, 3H), 2.32 (br s, 3H), 3.13 (br s, 3H), 4.90
(dd, J = 8.1, 5.2 Hz, 1H), 7.29 (s, 1H), 7.30 (s, 1H), 7.33—7.43 (m, 4H), 7.56 (s, 1H). 13C
NMR (100 MHz, CDCl3) ppm 22.3, 23.3, 24.7, 46.6, 65.4, 108.9, 126.6, 127.9, 128.4,
130.7, 139.2, 150.1, 152.1, 189.5.

HRMS (ESI) calcd. for C18H24N4O2 [M + H]+

329.1972, found 329.1972.
1-(1-(2-Amino-4-phenylpyrimidin-5-yl)-1H-1,2,3-triazol-4-yl)-3-methylbutan-1-ol
(3.10)
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To a solution of 3.9 (0.2 mmol) in ethanol (3 mL) under argon atmosphere was added
guanidine hydrochloride (0.5 mmol) and sodium ethoxide (0.5 mmol). The reaction
mixture was stirred under reflux for 15 h. The reaction mixture was then concentrated
under reduced pressure. The residue was extracted between DCM and water. The
organic layer was dried over sodium sulfate, and the solvent was removed by reduced
pressure affords the crude product as a yellow solid. Purification by flash column
chromatography on silica gel (ethyl acetate/hexane, 4:1) affords 3.10 as white solid
(80%). 1H NMR (400 MHz, CDCl3) ppm 0.91 (dd, J = 6.3, 1.7 Hz, 6H), 1.47–1.78 (m,
3H), 7.11–7.49 (m, 5H), 7.76 (s, 1H), 8.37 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm

21.5, 21.99, 24.4, 46.3, 64.5, 104.99, 121.1, 124.8, 128.0, 135.2, 152.6, 156.6, 162.8,
164.0. HRMS (ESI) calcd. for C17H20N6O [M + H]+ 325.1771, found 325.1763.
1-(1-(4'-isoButyl-2',4-diphenyl-[2,5'-bipyrimidin]-5-yl)-1H-1,2,3-triazol-4-yl)-3methylbutan-1-ol (3.11)

87

To a solution of 2.5 (0.4 mmol), freshly made using the method described before, in
ethanol (8 mL) under argon atmosphere was added 3.9 (0.2 mmol) and triethylamine (0.4
mmol). The reaction mixture was stirred under reflux for 14 h. The reaction mixture was
then concentrated under reduced pressure. The residue was extracted between DCM and
water. The organic layer was dried over sodium sulfate, and the solvent was removed by
reduced pressure to afford the crude product as a yellow solid. Purification by flash
column chromatography on silica gel (ethyl acetate/hexane, 1:1) affords 3.10 as white
solid. 1H NMR (400 MHz, CDCl3) ppm 0.94–0.98 (m, 12H), 1.64–1.80 (m, 4H), 2.10–
2.16 (m, 1H), 2.31–2.43 (m, 1H), 4.95– 5.03 (m, 1H), 7.38–7.41 (m, 5H), 7.51–7.55 (m,
4H), 8.55–8.59 (m, 2H), 9.09 (s, 1H), 9.48 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm

22.3, 22.9, 23.2, 24.8, 28.5, 45.0, 46.6, 65.5, 122.8, 128.1, 128.8, 131.3, 137.6, 153.1,
155.4, 159.6, 164.4, 169.9. HRMS (ESI) calcd. for C31H33N7O [M + H]+ 520.2819,
found 520.2810.
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Chapter Four:
Design and Synthesis of Hybrid Scaffold Non-peptidic -Helical Mimetics
4.1

Introduction

4.1.1

General scaffold of non-peptidic -helical mimetics
We have previously synthesized several analogs of 2,5-terpyrimidinylene scaffold

molecules, which aimed at mimicking the most in vitro active non-peptidic p53-MDM2
inhibitor (Yin et al., 2005a) that has been reported so far. Nevertheless, the reported nonpeptidic -helical mimetics have more diverted structures (Figure 2.2).
A common feature of those molecules is the presence of three directly bonded
rings as the backbone, positioned in a linear configuration. The ring fragments could be
either regular covalent-bonded rings (Davis et al., 2005), (Volonterio et al., 2007),
(Moisan et al., 2008) or rings formed by hydrogen bond (Ernst et al., 2003), (Estroff et
al., 2004), (Yin et al., 2005b), (Rodriguez and Hamilton, 2006). They are preferably
aromatic rings, for the benefit of the flat geometrical conformation associated. Each ring
bears an alkyl or aromatic side chain designed to mimic the side chains of the original
peptides. It is crucially that all alkyl or aromatic side chains point to the same face,
mimicking the i, i + 4(3), i + 7 positions of the peptides on the same face of the helix. An
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abstract model that stands for this series of non-peptide -helical mimetics is shown in
Figure 4.1.

Figure 4.1: Abstract structure of -helical mimetics
4.1.2

New library design strategy
From previous reports and studies, it was clear that it is very challenging to find

good p53/MDM2 antagonists: a favorable scaffold, favorable side chains, and a favorable
order of side chains all affect the activities of the antagonists. Thus, our strategy relied
on easily buildable scaffolds, amenable to library development, allowing the introduction
diverse side chains as well as terminal polar groups.
4.1.3

Introduction of the hybrid scaffold
The majority of non-peptidic -helical mimetics used iterative design, e.g. a, b, c,

in Figure 2.1 (Yin et al., 2005a), (Ernst et al., 2003), (Davis et al., 2005). The benefits
are the following: the alkyl or aromatic side chains are ensured to point to the same
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direction, and the synthesis is easy to design. However, iterative design usually involves
iterative linear synthesis, which is multistep and can be low yielding. As long as we can
make sure the side chains of the scaffold are pointed to the same direction, we could
consider the scaffold a good choice. We decided to focus on hybrid scaffolds, featuring
five-membered and six-membered aromatic rings for the simplification of synthesis. A
pyrimidine core was our six-membered rings candidate of choice, for its promising
properties shown in the previous projects carried out in our lab. Of the many aromatic
five-membered rings, we chose to use 1,2,3-triazole rings. The 1,2,3-triazole rings have
several characteristics suiting our needs. First, it could be easily synthesized from azides
and acetylenes (Chen et al., 2007), by the high yielding azide-alkyne Huisgen
cycloaddition, and the azides and acetylenes are readily with diverse sructures to ensure
the diversity of the 1,2,3-triazole rings. Second, the introduction of five-membered ring
with three nitrogen atoms would lower the logP value of the molecules (see discussions
of Table 2.1). In other words, the synthesized molecules have a higher water-solubility
potential if the scaffold contains more nitrogen atoms; thus, 1,2,3-triazole is a better
scaffold candidate than pyrimidine rings for the benefit of water solubility.
4.1.4

Strategy to extend the pyrimidine rings using Huisgen cycloaddition
1,2,3-triazole ring could be made from the reaction between azides and

acetylenes. If we can attach either an azide group or an acetylene group to the pyrimidine
ring, we could easily make a dimer (Scheme 4.1). With this in mind, the following dimer
synthesis has been carried out as a test of the 1,2,3-triazole ring strategy.
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Scheme 4.1: Synthetic strategy to make the hybrid dimer

4.2

Results and Discussion for introducing 1,2,3-triazole to the scaffold

4.2.1

Synthesis of 4-triazole pyrimidine hybrid dimer 4.6
The same procedure that was used to generate pyrimidine monomer 2.4 was

applied to the synthesis of monomer 4.2 (Scheme 4.2), bearing a hydrogen in place of a
cyano group at the 4-position. Further, we reacted the 4-alkyl group of compound 4.5
with an alkyl azide 4.7 to attach a 1,2,3-triazole ring to the 4-position of the pyrimidine
ring.
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Scheme 4.2: Synthesis of hybrid dimer 4.6
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In the first step, we reacted 1,1,1,-trifluoro-5-methyl-2,4-hexanedione with DMFDMA to form an -unsaturated ketones 4.1. This is an interesting reaction, because the
product of the reaction is dependent on the electronegativity properties of the group
adjacent R1 (Scheme 4.3). If it is an alkyl group, R1 will stay in the final molecule; on the
other hand, if R1 is a strong electron-withdrawing group, e.g. CF3, then the whole R1CO
group will be eliminated from the final molecules.
Scheme 4.3: Comparison of different substituted 1,3-diketones reacting with DMF-DMA

The mechanism of this reaction has not been studied, a possible mechanism is
proposed in Scheme 4.4.
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Scheme 4.4: One possible mechanism of 1,3-diketone reacting with DMF-DMA

The tautomer of 1,1,1,-trifluoro-5-methyl-2,4-hexanedione a acts like a
nucleophile to attack the iminium salt formed after DMF-DMA eliminates one
methoxide. After the formation of the tetrahedral intermediate c, a second methoxide
will be kicked out by the lone pair electron on the nitrogen atom to form the intermediate
d. There are two possible reactions for the intermediate d. If R1 is a regular alkyl group,
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a regular E2 reaction will take place, the -proton will be eliminated to form the product
e. However, if the R1 group is a strong enough electron-withdrawing group, the adjacent
carbonyl group would be activated so it can be a good electrophile towards MeO/MeOH.
After the attack of MeO/MeOH, the carbon-carbon bond on the other side of the carbonyl
group will be broken, that pair of electrons will become the pi electrons of a double bond.
One way to prove this mechanism is that, in this case, methyl trifluoroacetate should be a
side product.
After the -unsaturated ketone 4.1 was prepared, it underwent a cyclization
with guanidine to form a pyrimidine ring (Scheme 4.2). This reaction occurs under the
same condition we utilized for the -unsaturated -cyanoketones’ cyclization, even
though the -unsaturated ketone 4.1 is less reactive due to the lack of the electron
withdrawing cyano group. Then an iodination at the least electron deficient position of
the pyrimidine ring (Shepherd and Fellows, 1948), the 5-position, gave us the iodide
compound 4.3.

The iodide compound 4.3 underwent Sonogashira cross-coupling

reaction (Chen et al., 2007), coupling an acetone-protected acetylene to the pyrimidine
ring. Deprotection of the acetylene using potassium hydroxide in toluene at elevated
temperature gave us the unprotected acetylene product 4.5 (Watanabe et al., 2009). This
is the synthesis of the acetylene half for the Huisgen cycloaddition.
For the azide half, we should be able to use any alkyl azides or azide derivatives
of amino acids. We used benzyl azide 4.7 for it is easy synthesis (Alvarez and Alvarez,
1997).
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Finally, Huisgen cycloaddition between 4.5 and 4.7 under standard condition gave
the 1,2,3-triazole 4.6 in good yield.
4.2.2

Benefits of the 1,2,3-triazole ring
The polarity of dimer 4.6 is the highest among all the non-peptidic -helical

mimetics dimers that we have synthesized. The synthesis to attach a 1,2,3-triazole ring to
the 4-position of a pyrimidine ring is easy and high yielding. The combination of the two
factors makes the 1,2,3-triazole ring modified scaffold promising.
4.2.3

Synthesis of 2-triazole pyrimidine hybrid dimer 4.13
From the discussion above, we have successfully developed a way to attach a

1,2,3-triazole ring to the 4-position of the pyrimidine rings.

We also explored the

possibility of attaching a 1,2,3-triazole ring to the 2-position of the pyrimidine rings.
To form a 1,2,3-triazole ring at the 2- position of the pyrimidine ring, we can
either attach an azide group or an acetylene group. Initial attempts to replace the 2chloride on the pyrimidines with actylide anion failed. The acetylene amidine underwent
self-polymerization, therefore, cannot be used as the starting material to synthesize the
pyrimidines. Therefore, a better option is to attach an azide group to the 2-position of the
pyrimidine rings.

Again, direct replacement of 2-chloro pyrimidine with azide

derivatives did not produce any product, which was inconvenient also because of the
difficulty of synthesizing the 2-chloro-4-alkyl-pyrimidines (Scheme 4.8). In the end, we
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deployed the reaction of hydrazine reacting with nitrous acid to synthesis the azide; and
successfully attached a 1,2,3-triazole ring to the 2-position of pyrimidine rings.
We found that DMF-DMA can react with all kinds of ketones besides the -cyano
ketones, as long as the -position contains at least two hydrogen atoms (Scheme 4.5). If
the -position is attached to some electron-withdrawing group, e.g. cyano group, nitro
group, 1,2,3,-triazole group, this reaction occurs at room temperature; whereas, higher
temperatures are required for less activated ketones.
Scheme 4.5: General methodology to synthesize -unsaturated ketones from ketones

The -unsaturated ketone 4.9d reacted with protected aminoguanidine in the
microwave giving the pyrimidine ring product 4.10 (Scheme 4.6). The hydrazine group
of 4.10 is protected as imine (Martins et al., 2004), which is normally acid labile.
However, this imine group is very stable, as a result of the conjugated system, so even
concentrated hydrochloride acid and sulfuric acid could not break down the imine group.
Luckily, with a large excess of hydrazine hydrate, hydrazine product 4.11 could be
formed (Gonzalez, 1988). The reaction to remove the benzylaldehyde protecting group
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should be through a competition mechanism, where hydrazine competes with the
hydrazine group of 4.10 for the benzylaldehyde. Compound 4.11 reacts with nitrous acid
to form a 2-azido pyrimidine 4.12 (Lindsay and Allen, 1942). This azide compound 4.12
reacted

with

commercially

available

5-methyl-1-hexyn-3-ol

through

Huisgen

cycloaddition to form the compound 4.13, which has a 1,2,3,-triazole ring attached at the
Scheme 4.6: Synthesis of hybrid dimer 4.13
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2-position of the pyrimidine ring.
Again, compound 4.13 is as polar as compound 4.6, both are more polar than the
pyrimidine dimers that we have synthesized.
4.2.4

Evaluation 1,2,3-triazole ring as a fragment in our scaffold
So far, we have proven the possibility of attaching 1,2,3-triazole ring to both 2-

position (top) and 5-position (bottom) of a pyrimidine ring. Both compounds 4.6 and
4.13 are significantly more polar than the other pyrimidine dimers that we have
previously synthesized. Unfortunately, we failed all the attempts to attach iodine at the 5position of 4.13 (Shepherd and Fellows, 1948), (Beierlein et al., 2008), (Guillard and
Viaud-Massuard, 2008), thus no trimer of this series has been synthesized yet. The
failure of this reaction might be the result of the switch from the electron-donating group
NH2 to electron-withdrawing 1,2,3-triazole ring.
Nevertheless, the 1,2,3-triazole ring incorporation showed promising result
toward our goal of water-soluble non-peptidic -helical mimetic library design and
synthesis.
4.3

Results and Discussion for introducing amino acids to the scaffold

4.3.1

Possibility of introducing amino acids to the scaffold
Even though most of the libraries that have been developed so far feature three

flat rings (mostly aromatic) that have been attached linearly (Figure 2.1) (Yin et al.,
2005a), (Davis et al., 2005), (Moisan et al., 2008), (Volonterio et al., 2007), this might
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not be an essential requirement to this series of non-peptidic -helical mimetics.
Computational studies showed that the side chain of the 2-amino acid on the pyrimidine
ring is at the right position, i + 7 (Figure 4.2).

Figure 4.2: Trimer with an amino acid in the scaffold fitting the abstract scaffold
There are several advantages of introducing an amino acid to the scaffold. Its side
chain is in the right position; introduction of amino acid will not increase the overall
lipophilicity of the molecule (it should decrease the lipophilicity for amino acids do not
contain the aromatic system in the backbone), and the nitrogen carbon bond that connects
the amino acid to the pyrimidine ring will not be labile like the peptide bond. Most
importantly, it is very convenient to introduce an amino acid to the pyrimidine ring by
aromatic substitution reactions; thus the introduction of amino acids to the scaffold fits
our need to simplify the synthesis.
4.3.2

Testing of the new scaffold
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Again, we would like to keep the second fragment of our scaffold a pyrimidine
ring. This is because it is relatively easy to introduce new groups to the 2- and 5positions of 4-alkyl pyrimidines. Between the 2- and 5-position, we decided to put the
amino acids in the 2-position.
For the third fragment of our scaffold, we decided to use a 1,2,3-triazole, because
of its promising properties that we have proven before. The pyrimidine ring will have an
electron-donating nitrogen atom at the 2-position, so it would be possible to connect a
1,2,3-triazole ring to the 5-position.
Our new scaffold is shown in Figure 4.3.

Figure 4.3: Possible conformation of the new scaffold
4.3.3

Retrosynthesis of the trimer
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The target molecule g could be synthesized from the dimer h using the method
developed (Scheme 4.7). Compound h could, in turn, be synthesized from the 2-chloro4-alkyl-pyrimidine i.
Scheme 4.7: Retrosynthesis of the hybrid trimer

Unfortunately, compound i is relatively challenging to synthesize. For the two
methods that we have tried (Scheme 4.8), neither one gave us promising results. We first
tried the diazonium salt route to convert a NH2 group to a chloride compound 4.14
(Dhanda et al., 1999). This method gave us about a 30% yield, with a lot of starting
material remaining. In the other route, we attempted to react aminocyanogen with HCl
gas to produce chloroamidine hydrochloride 4.15 in about a 30% yield (Henderson et al.,
2006).

Then we condensed the chloroamidine 4.15 with the -unsaturated -

cyanoketone 2.3d to form the 2-chloropyrimidine 4.16. The second step has a 40% yield,
so the overall yield to prepare 4.16 is around 12%.
In summary, neither one of methods that have been tried provided us promising
results to pursue.
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Scheme 4.8: Synthesis of the 2-chloro-pyrimidine ring

4.3.4

Modification of the new target scaffold and the retrosynthesis route
Some of the molecules that have been developed so far used ether groups instead

of alkyl group as the side chains to mimic the side chains of -helices (Figure 2.1) (Ernst
et al., 2003), (Estroff et al., 2004), (Yin et al., 2005b). If we modify our target molecule
from g to g’ (Scheme 4.9), the overall geometry of the molecule should not be changed,
but the synthesis is greatly simplified.
Target molecule g’ could be synthesized from the dimer h’, using the strategy that
has been well developed (Scheme 4.2). The extra oxygen atom at the 4-position of the
pyrimidine ring can further help the iodination reaction of the h’ molecule. The dimer h’
could be synthesized by nucleophilic aromatic substitution reaction one step from the
monomer i’. Because of the reactivity difference between the two chlorine atoms on the
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commercially available molecule 2,4-dichloropyrimidine, the 4-chloride could be
substituted selectively at room temperature to make the monomer i’.
Scheme 4.9: Modification of the target molecule

4.3.5

Synthesis of the trimer 4.21
The synthesis is shown in Scheme 4.10. Benzyl alcohol was deprotonated using

sodium hydride, it replaced the 4-chloride of the 2,4-dichloropyrimidine at room
temperature (Irie et al., 2008). Trace amounts of 2,4-dibenzyloxylpyrimidine product
could be detected, but the mono-substitution reaction product 4-benzyloxylpyrimidine
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Scheme 4.10: Synthesis of trimer 4.22
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4.17 was the predominate product, with a yield of 78%. Then, a free amino group of an
amino acid replaced the 2-chloride at 155 oC under microwave irradiation (Humphries et
al., 2009). The yield of this step is relatively low; fortunately, there is no side reaction
occurring, allowing us to recover most of the starting material left over.

Next, an

iodination reaction gave us compound 4.19 in good yield. Subsequently, Sonogashira
reaction coupled an ethynyltrimethylsilane to the dimer. We did not use 2-methyl-3butyn-2-ol here, because although we could couple it to our dimer, the potassium
hydroxide that was used to deprotect the acetone group in the next step also reacted with
another part of the molecule. Therefore, we chose TMS protected acetylene, and then
took the TMS group off by TBAF under mild conditions to synthesize the acetylene half
4.20.
For the azide reactant, we could very well use the benzyl azide 4.7 previously
synthesized. But we decided to test the compatibility of azide derivatives of amino acids
with our scafford. The azide derivative of valine 4.22 was synthesized by a reported
procedure (Goddard-Borger and Stick, 2007), using 1H-imidazole-1-sulfonyl azide as the
azide source, potassium carbonate as base, and copper sulfate pentahydrate as catalyst.
The Huisgen cycloaddition between acetylene 4.20 and azide 4.22 went very well,
getting almost quantitative yield.
4.3.6

Properties of the timer 4.21
Trimer 4.21 has greatly improved water solubility when compared to compound

2.8, and 3.10. Also, trimer 4.17 is synthetically the easiest to prepare among the three
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trimer scaffolds (2.8, 3.10, and 4.17) that we have developed; its synthesis involves seven
steps, six of which are excellent yielding reactions. Due to the good water solubility as
well as its amenability to library-synthesis, the scaffold of trimer series 4.17 appears to be
the most promising -helix mimetics.

The bio-activity of compound 4.17 against

p53/MDM and Bcl-xL are currently under investigation.
4.4

Biological testing of 4.6 and 4.13
Dimer compounds 4.6 and 4.13 was tested in Enzyme-linked immunosorbent

assay (ELISA) assay against p53/MDM2 interaction (Figure 4.4, 4.6 in blue, 4.13 in
yellow).

Figure 4.4: Elisa results of 4.6 and 4.13
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Dimer 4.13 showed promising results at lower concentration. But its activity
remained unchanged after certain concentration. This indicates that there might still be a
solubility problem. Dimer 4.6 also showed some activity against p53/MDM2.
Considering the sizes of 4.6 and 4.13, we can conclude that our non-peptidic helical scaffolds are properly designed.

The activities of trimer 4.21 are under

investigation.
4.5

Conclusion
The work shown in this chapter provide a new generation of non-peptidic -

helical mimetics. There are three basic principles that are leading our design. The side
chains of our designed molecules should act as mimetics of the side chains of an -helix.
Second, our molecules should possess improved water solubility. Third, the molecules
should be easy to synthesize to generate a focused library. Based on those three criteria,
we introduced the 1,2,3-triazole rings and amino acids into the scaffold, and those two
scaffold segments showed very promising properties towards the principle. Our target
molecule has been redesigned, and one analog 4.21 has synthesized. The synthesized
molecule is now under biological testing to check bio-activities against p53/MDM and
Bak/Bcl-xL.
4.6

Experimental Section

1-(Dimethylamino)-4-methylpent-1-en-3-one (4.1)
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To a solution of commercially available 1,1,1-trifluoro-5-methyl-2,4-hexanedione (7.7
mmol) in THF (5 ml) under argon atmosphere was added DMF-DMA (10.0 mmol). The
reaction mixture was stirred overnight. The reaction mixture was concentrated under
reduced pressure to afford the crude product as brown solid. Purification by flash column
chromatography on silica gel (ethyl acetate/hexanes, 4:1) affords 4.1 as a colorless oil
(0.84 g, 77%).

1

H NMR (400 MHz, CDCl3) ppm 1.07 (dd, J = 6.9, 1.7 Hz, 6H), 2.46–

2.59 (m, 1H), 2.81 (br s, 3H), 3.00 (br s, 3H), 5.02 (d, J = 12.6 Hz, 1H), 7.54 (d, J = 12.6
Hz, 1H).

13

C NMR (100 MHz, CDCl3) ppm 19.8, 37.2, 39.8, 44.9, 93.9, 152.7, 202.5.

4-iso-Propylpyrimidin-2-amine (4.2)

To a solution of 4.1 (5.1 mmol) and guanidine hydrochloride (25.3 mmol) in anhydrous
ethanol (10 mL) under argon atmosphere was added triethylamine (25.3 mmol). The
reaction mixture was stirred in reflux for 24 h.

The reaction mixture was then

concentrated under reduced pressure. The residue was extracted between DCM and
water. The organic layer was dried over sodium sulfate, and the solvent was removed
under reduced pressure to afford the crude product as a yellow oil. Purification by flash
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column chromatography on silica gel (ethyl acetate/hexane, 2:1) affords 4.2 as a white
solid (0.41 g, 58%).

1

H NMR (400 MHz, CDCl3) ppm 1.22 (d, J = 7.0 Hz, 6H), 2.77

(hept, J = 6.9 Hz, 1H), 5.09 (br. s, 2H), 6.49 (d, J = 5.2 Hz, 1H), 8.17 (d, J = 5.2 Hz, 1H).
13

C NMR (100 MHz, CDCl3) ppm 21.9, 36.1, 108.6, 158.3, 163.1, 177.4.

5-Iodo-4-isopropylpyrimidin-2-amine (4.3)

A suspension of 4.2 (0.4 mmol) and mercury(II) acetate (0.2 mmol) in water (4 mL), was
heated to be boiling for 2 min, and a hot solution of iodine (0.4 mmol) in 1,4-dioxane (4
mL) was added. The reaction mixture was stirred at 100 ºC for 30 min. After the
reaction, a mixture of potassium iodide and sodium sulfite was added to the reaction
mixture, and the mixture was stirred overnight.

The reaction mixture was then

concentrated under reduced pressure. The residue was extracted between DCM and
water. The organic layer was dried over sodium sulfate, and the solvent was removed
under reduced pressure to afford the crude product as a yellow oil. Purification by flash
column chromatography on silica gel (ethyl acetate/hexane, 1:3) affords 4.3 as a yellow
solid (68 mg, 65%).

1

H NMR (400 MHz, CDCl3) ppm 1.17 (d, J = 6.8 Hz, 6H), 3.19

(hept, J = 6.7 Hz, 1H), 5.31 (br. s, 2H), 8.37 (s, 1H).
21.0, 37.5, 81.1, 162.7, 164.9, 176.1.

13

C NMR (100 MHz, CDCl3) ppm

HRMS (ESI) calcd. for C7H10IN3 [M + H]+

263.9992, found 264.0174.
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4-(2-Amino-4-isopropylpyrimidin-5-yl)-2-methylbut-3-yn-2-ol (4.4)

To a solution of 4.3 (0.3 mmol) and 2-methyl-3-butyn-2-ol (0.3 mmol) in anhydrous
acetonitrile

(5

mL)

under

argon

atmosphere

was

added

tetrakis(triphenylphosphine)palladium(0) (0.009 mmol), copper(I) iodide (0.02 mmol)
and triethylamine (1.5 mL). The reaction mixture was stirred under reflux for 20 h. The
reaction mixture was then concentrated under reduced pressure.

The residue was

extracted between ethyl acetate and water. The organic layer was washed with brine,
dried over sodium sulfate, and the solvent was removed under reduced pressure to afford
the crude product as a yellow oil. Purification by flash column chromatography on silica
gel (ethyl acetate/hexane, 2:1) affords 4.4 as a white solid (40 mg, 73%). HRMS (ESI)
calcd. for C12H17N3O [M + H]+ 220.1444, found 220.1497.
5-Ethynyl-4-isopropylpyrimidin-2-amine (4.5)
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To a solution of 4.4 (0.1 mmol) in toluene (5 mL) was added was added potassium
hydroxide (0.5 mmol). The reaction mixture was stirred at 70 ºC for 3 h. The reaction
mixture was then concentrated under reduced pressure.

The residue was extracted

between dichloromethane and saturated ammonium chloride aqueous solution.

The

organic layer was dried over sodium sulfate, and the solvent was removed under reduced
pressure to afford the crude product as a yellow oil. Purification by flash column
chromatography on silica gel (ethyl acetate/hexane, 1:2) affords 4.5 as a colorless oil (11
mg, 75%).
5-(1-Benzyl-1H-1,2,3-triazol-4-yl)-4-isopropylpyrimidin-2-amine (4.6)

To a solution of 4.4 (0.1 mmol) and benzyl azide 4.7 (0.1 mmol) in tert-butanol (2 mL)
was added a solution of (+)-sodium L-ascorbate (0.1 mmol) in water (1 mL), and then a
solution of copper(II) sulfate pentahydrate (0.01 mmol) in water (1 mL). The reaction
mixture was stirred at room temperature for 24 h.

The reaction mixture was then

concentrated under reduced pressure. The residue was extracted between ethyl acetate
and water. The organic layer was washed with brine, dried over sodium sulfate, and the
solvent was removed under reduced pressure to afford the crude product as a yellow oil.
Purification by flash column chromatography on silica gel (ethyl acetate/hexane, 2:1)
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affords 4.6 as a white solid (14 mg, 70%). 1H NMR (400 MHz, CDCl3) ppm 1.19 (d, J =
6.7 Hz, 6H), 3.24–3.36 (m, 1H), 5.07 (br. s, 2H), 5.59 (s, 2H), 7.30–7.44 (m, 5H), 7.47 (s,
1H), 8.33 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm 21.6, 29.9, 31.8, 54.5, 121.6, 128.3,

129.4, 134.7, 144.0, 158.4, 162.8, 174.7.
Benzyl azide (4.7)

Sodium azide (10.0 mmol) was dissolved in DMSO (20 mL) and the solution was stirred
at room temperature for 12 h. To this solution was added benzyl bromide (5.0 mmol).
The reaction mixture was stirred at room temperature for 4 h. The reaction mixture was
then concentrated under reduced pressure using the Biotage V10. The residue was
extracted between diethyl ether and water. The organic layer was washed with brine,
dried over sodium sulfate, and the solvent was removed under reduced pressure to afford
the crude product as a colorless oil. Purification by flash column chromatography on
silica gel (ethyl acetate/hexane, 1:20) affords 3.6 as a colorless oil (0.47 g, 71%).
2-Benzylidenehydrazinecarboximidamide hydrochloride (4.8)

To a solution of aminoguanidine hydrochloride (1.1 mmol) in ethanol (2 mL) was added
benzaldehyde (1.0 mmol). The reaction mixture was placed in a microwave reactor for
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10 min. at 160 ºC. The reaction mixture was then concentrated under reduced pressure to
afford the intermediate 4.8, which was used in the next step without further purification.
4-(Dimethylamino)but-3-en-2-one (4.9a)

The mixture of acetone (6.8 mmol) and DMF-DMA (6.8mmol) was stirred under reflux
for 16 h. The reaction mixture was then concentrated under reduced pressure to afford
4.9a as a yellow solid, which was used in the next step without further purification.
1-(Dimethylamino)-4-methylhex-1-en-3-one (4.9b)

The mixture of commercially available 3-methyl-2-pentanone (8.1 mmol) and DMFDMA (10.4 mmol) was stirred at 85 ºC for 16 h.

The reaction mixture was then

concentrated under reduced pressure to afford 4.9b as a yellow solid, which was used in
the next step without further purification. 1H NMR (400 MHz, CDCl3) ppm 0.81 (t, J =
7.4 Hz, 3H), 1.01 (d, J = 6.9 Hz, 3H), 1.32 (td, J = 14.0, 7.0 Hz, 1H), 1.60 (dq, J = 22.2,
7.4 Hz, 1H), 2.29 (dq, J = 13.8, 6.9 Hz, 1H), 2.87 (s, 6H), 4.98 (d, J = 12.6 Hz, 1H), 7.50
(d, J = 12.6 Hz, 1H).
1-Cyclopropyl-3-(dimethylamino)prop-2-en-1-one (4.9c)
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The mixture of commercially available cyclopropyl methyl ketone (10.1 mmol) and
DMF-DMA (13.4 mmol) was stirred at 85 ºC for 16 h. The reaction mixture was then
concentrated under reduced pressure to afford 4.9c as a yellow solid, which was used in
the next step without further purification.

1

H NMR (400 MHz, CDCl3) ppm 0.70–0.77

(m, 2H), 0.96–1.03 (m, 2H), 1.70 (br. s, 3H), 1.74–1.84 (m, 1H), 5.19 (d, J = 12.6 Hz,
1H), 7.55 (d, J = 12.6 Hz, 1H).
3-(Dimethylamino)-1-phenylprop-2-en-1-one (4.9d)

The mixture of commercially available acetophenone (4.3 mmol) and DMF-DMA (5.6
mmol) was stirred at 85 ºC for 16 h. The reaction mixture was then concentrated under
reduced pressure to afford 4.9d as a yellow solid, which was used in the next step without
further purification. 1H NMR (400 MHz, CDCl3) ppm 2.92 (br. s, 3H), 3.14 (br. s, 3H),
5.71 (d, J = 12.4 Hz, 1H), 7.34–7.49 (m, 3H), 7.80 (d, J = 12.4 Hz, 1H), 7.86–7.92 (m,
2H).
2-(2-Benzylidenehydrazinyl)-4-phenylpyrimidine (4.10)
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To a solution of 4.8 (4.5 mmol) in anhydrous ethanol (3 mL) was added 4.9d (4.4 mmol).
The reaction mixture was placed in a microwave reactor for 2 h at 155 ºC. The reaction
mixture was then concentrated under reduced pressure.

The residue was extracted

between dichloromethane and water. The organic layer was dried over sodium sulfate,
and the solvent was removed under reduced pressure to afford the crude product as a
yellow solid.

Purification by flash column chromatography on silica gel (ethyl

acetate/hexane, 1:3) affords 4.10 as a yellow solid (0.76 g, 64%).

1

H NMR (400 MHz,

CDCl3) ppm 7.20 (d, J = 5.2 Hz, 1H), 7.30–7.39 (m, 3H), 7.45–7.53 (m, 3H), 7.70 (d, J =
6.7 Hz, 2H), 7.79 (s, 1H), 8.08 (dd, J = 6.5, 2.9 Hz, 2H), 8.58 (d, J = 5.1 Hz, 1H), 9.27 (s,
1H).

13

C NMR (100 MHz, CDCl3) ppm 109.6, 127.4, 127.4, 128.8, 129.1, 131.2, 134.4,

137.0, 142.7, 159.4, 160.2, 165.7.
2-Hydrazinyl-4-phenylpyrimidine (4.11)
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To a solution of 4.10 (0.1 mmol) in ethanol (5 mL) was added hydrazine hydrate (5 mL).
The reaction mixture was stirred under reflux for 12 h. The reaction mixture was then
concentrated under reduced pressure to afford 4.11 as a yellow oil, which was used in the
next step without further purification.
2-Azido-4-phenylpyrimidine (4.12)

To a solution of 4.11 (0.1 mmol) in acetic acid (0.5 mL) was added a solution of sodium
nitrite (0.7 mmol) in water (0.5 mL).
temperature for 24 h.

The reaction mixture was stirred at room

The reaction mixture was then concentrated under reduced

pressure. The residue was extracted between dichloromethane and sodium bicarbonate
saturated aqueous solution. The organic layer was dried over sodium sulfate, and the
solvent was removed under reduced pressure to afford the crude product as a yellow oil.
Purification by flash column chromatography on silica gel (ethyl acetate/hexane, 1:5)
affords 4.12 as a white solid (16 mg, 57%). 1H NMR (400 MHz, CDCl3) ppm 7.47 (d, J
= 5.3 Hz, 1H), 7.49–7.57 (m, 3H), 8.11 (dd, J = 7.4, 1.9 Hz, 2H), 8.63 (d, J = 5.2 Hz,
1H).

13

C NMR (100 MHz, CDCl3) ppm 112.7, 127.5, 129.3, 131.9, 135.8, 159.8, 166.4.

HRMS (ESI) calcd. for C10H7N5 [M + H]+ 198.0774, found 198.0808.
3-Methyl-1-(1-(4-phenylpyrimidin-2-yl)-1H-1,2,3-triazol-4-yl)butan-1-ol (4.13)
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To a solution of 4.12 (0.1 mmol) and commercially available 5-methyl-1-hexyn-3-ol (0.1
mmol) in tert-butanol (2 mL) was added a solution of (+)-sodium L-ascorbate (0.1 mmol)
in water (1 mL), and then a solution of copper(II) sulfate pentahydrate (0.03 mmol) in
water (1 mL). The reaction mixture was stirred at room temperature for 24 h. The
reaction mixture was then concentrated under reduced pressure.

The residue was

extracted between ethyl acetate and water. The organic layer was washed with brine,
dried over sodium sulfate, and the solvent was removed under reduced pressure to afford
the crude product as a yellow oil. Purification by flash column chromatography on silica
gel (ethyl acetate/hexane, 3:1) affords 4.13 as a white solid (14 mg, 70%). 1H NMR (400
MHz, CDCl3) ppm 0.95 (d, J = 6.3 Hz, 6H), 1.72–1.86 (m, 3H), 5.06 (dd, J = 8.3, 4.7 Hz,
1H), 7.48– 7.54 (m, 3H), 7.71 (d, J = 5.3 Hz, 1H), 8.14 (dd, J = 7.8, 1.8 Hz, 2H), 8.58 (s,
1H), 8.83 (d, J = 5.3 Hz, 1H).

13

C NMR (100 MHz, CDCl3) ppm 22.2, 23.5, 24.8, 29.9,

45.5, 65.6, 116.2, 119.7, 127.7, 129.5, 132.37, 135.3, 160.0, 166.8. HRMS (ESI) calcd.
for C17H19N5O [M + H]+ 310.1662, found 310.1688.
4-(tert-butyl)-2-chloropyrimidine-5-carbonitrile (4.14)
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To a solution of 2.4i (0.6 mmol) and antimony(III) chloride (1.2 mmol) in anhydrous
chloroform (5 mL) under argon atmosphere was added iso-pentyl nitrite (2.0 mmol) very
slowly. The reaction mixture was stirred in reflux for 7 h. The reaction mixture was then
poured into a saturated sodium bicarbonate aqueous solution. The mixture was filtered
through CeliteTM. The filtrate was extracted with diethyl ether. The organic layer was
washed with brine, dried over sodium sulfate, and the solvent was removed under
reduced pressure to afford the crude product as a yellow oil. Purification by flash column
chromatography on silica gel (ethyl acetate/hexane, 1:10) affords 4.14 as a colorless oil
(30%).

1

H NMR (400 MHz, CDCl3) ppm 1.46 (s, 9H), 8.71 (s, 1H).

13

C NMR (100

MHz, CDCl3) ppm 28.7, 29.9, 40.3, 105.8, 115.6, 163.0, 164.1, 183.0.
Carbamimidic chloride hydrochloride(4.15)

To a solution of cyanamide (11.7 mmol) in diethyl ether (50 mL) was added HCl (g) for
30 min. The reaction mixture was stirred at room temperature for an additional 5 h. The
reaction mixture was filtered through CeliteTM. The residue was rinsed with lots of
diethyl ether to afford the crude product 4.15 as a white solid (0.40g, 30%), which was
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used in the next step without further purification. 1H NMR (400 MHz, DMSO) ppm 6.25
(br. s, 2H), 12.17 (br. s, 2H).

13

C NMR (100 MHz, DMSO) ppm 155.2.

2-Chloro-4-isobutylpyrimidine-5-carbonitrile (4.16)

To a solution of 4.15 (0.5 mmol) and 2.3d (0.4 mmol) in anhydrous 1,4-dioxane (3 mL)
under argon atmosphere was added triethylamine (0.5 mmol). The reaction mixture was
stirred at reflux for 13 h. The reaction mixture was then concentrated under reduced
pressure. The residue was extracted between DCM and water. The organic layer was
dried over sodium sulfate, and the solvent was removed under reduced pressure to afford
the crude product as a yellow oil. Purification by flash column chromatography on silica
gel (ethyl acetate/hexane, 1:3) affords 4.16 as a colorless oil (40%). 1H NMR (400 MHz,
CDCl3) ppm 0.98 (d, J = 6.7 Hz, 6H), 2.12–2.25 (m, 1H), 2.66 (d, J = 7.3 Hz, 2H), 5.49
(s, 2H), 8.45 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm 22.6, 22.7, 28.8, 45.6, 116.7,

162.1, 162.9, 175.0.
4-(Benzyloxy)-2-chloropyrimidine (4.17)
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To a suspension of sodium hydride (12.6 mmol) in anhydrous N,N-dimethylformamide (5
mL) at 0 ºC in an ice-bath under argon atmosphere was added benzyl alcohol (5.8 mmol)
slowly. To this solution was added a solution of 2,4-dichloropyrimidine (5.8 mmol) in
tetrahydrofuran. The reaction mixture was stirred at room temperature for 24 h. The
reaction mixture was then concentrated under reduced pressure.

The residue was

extracted between DCM and water. The organic layer was dried over sodium sulfate, and
the solvent was removed under reduced pressure to afford the crude product as a yellow
oil. Purification by flash column chromatography on silica gel (ethyl acetate/hexane, 1:5)
affords 4.17 as a white solid (1.0 g, 78%).

1

H NMR (400 MHz, CDCl3) ppm 5.43 (s,

2H), 6.71 (d, J = 5.7 Hz, 1H), 7.36–7.47 (m, 5H), 8.31 (d, J = 5.7 Hz, 1H).

13

C NMR

(100 MHz, CDCl3) ppm 69.4, 107.6, 128.8, 128.9, 128.9, 135.4, 159.1, 160.4, 170.3.
Methyl 2-((4-(benzyloxy)pyrimidin-2-yl)amino)-4-methylpentanoate (4.18)

To a solution of 4.17 (0.8 mmol) and L-leucine methyl ester hydrochloride (1.6 mmol) in
anhydrous ethanol (3 mL) was added sodium methoxide (1.6 mmol). The reaction
mixture was placed in a microwave reactor for 2 h at 160 ºC. The reaction mixture was
then concentrated under reduced pressure.

The residue was extracted between

dichloromethane and water. The organic layer was dried over sodium sulfate, and the
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solvent was removed under reduced pressure to afford the crude product as a yellow
solid. Purification by flash column chromatography on silica gel (ethyl acetate/hexane,
1:3) affords 4.18 as a white solid (49 mg, 39%). 1H NMR (400 MHz, CDCl3) ppm0.96
(dd, J = 10.3, 6.5 Hz, 6H), 1.58–1.87 (m, 3H), 3.70 (s, 3H), 4.55–4.69 (d, J = 5.5 Hz,
1H), 5.31 (s, 2H), 6.10 (d, J = 5.6 Hz, 1H), 7.28–7.44 (m, 4H), 8.03 (d, J = 5.2 Hz, 1H).
13

C NMR (100 MHz, CDCl3) ppm 22.2, 23.1, 25.1, 41.8, 52.3, 53.3, 67.7, 128.3, 128.7,

136.8, 169.8, 170.4, 174.8. HRMS (ESI) calcd. for C18H23N3O3 [M + H]+ 330.1812,
found 330.1852.
Methyl 2-((4-(benzyloxy)-5-iodopyrimidin-2-yl)amino)-4-methylpentanoate (4.19)

To a suspension of 4.18 (0.2 mmol) and mercury(II) acetate (0.1 mmol) in water (2 mL),
that was heated to boiling for 2 min, was added a hot solution of iodine (0.2 mmol) in
1,4-dioxane (2 mL). The reaction mixture was stirred at 100 ºC for 2 h. After the
reaction, a mixture of potassium iodide and sodium sulfite was added to the reaction
mixture, and the mixture was stirred overnight.

The reaction mixture was then

concentrated under reduced pressure. The residue was extracted between DCM and
water. The organic layer was dried over sodium sulfate, and the solvent was removed
under reduced pressure to afford the crude product as a yellow oil. Purification by flash
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column chromatography on silica gel (ethyl acetate/hexane, 1:5) affords 4.19 as a yellow
solid (42 mg, 62%). 1H NMR (400 MHz, CDCl3) 0.95 (dd, J = 13.5, 6.3 Hz, 6H), 1.53–
1.85 (m, 3H), 3.70 (s, 3H), 4.43–4.68 (m, 1H), 5.37 (s, 2H), 7.37 (ddd, J = 25.0, 18.5, 7.5
Hz, 2H), 7.28–7.48 (m, 5H), 8.26 (s, 1H).

13

C NMR (100 MHz, CDCl3) ppm 22.1, 23.1,

25.1, 52.4, 61.3, 68.6, 127.6, 128.2, 128.7, 136.5, 161.4, 164.8, 167.0, 173.9.
Methyl 2-((4-(benzyloxy)-5-ethynylpyrimidin-2-yl)amino)-4-methylpentanoate (4.20)

Step 1: To a solution of 4.19 (0.1 mmol) and ethynyltrimethylsilane (0.2 mmol) in
anhydrous

acetonitrile

(3

mL)

under

argon

atmosphere

was

added

tetrakis(triphenylphosphine)palladium(0) (0.003 mmol), copper(I) iodide (0.007 mmol)
and triethylamine (1 mL). The reaction mixture was stirred under reflux for 20 h. The
reaction mixture was then concentrated under reduced pressure. The residue was purified
by flash column chromatography on silica gel (ethyl acetate/hexane, 1:5) to afford the
intermediate as a white solid, which was used in the next step without further
purification.
Step 2: To a solution of the intermediate from step 1 in anhydrous tetrahydrofuran (1 mL)
at 0 ºC in an ice-bath under argon atmosphere was added tetrabutylammonium fluoride
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(0.03 mmol). The reaction mixture was stirred at 0 ºC for 10 h. The reaction mixture
was then concentrated under reduced pressure. The residue was extracted between DCM
and water.

The organic layer was dried over sodium sulfate, and the solvent was

removed under reduced pressure to afford the crude product as a yellow oil. Purification
by flash column chromatography on silica gel (ethyl acetate/hexane, 1:5) affords 4.20 as
a white solid (30 mg, 92%). 1H NMR (400 MHz, CDCl3) ppm 0.79–1.02 (m, 6H), 1.58–
1.83 (m, 3H), 3.27 (s, 1H), 3.69 (s, 3H), 4.46–4.60 (m, 1H), 5.41 (s, 2H), 6.04 (br. s, 1H),
7.31 (d, J = 7.2 Hz, 1H), 7.36 (t, J = 7.3 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 8.21 (s, 1H).
13

C NMR (100 MHz, CDCl3) ppm 23.1, 25.5, 29.9, 41.5, 52.4, 53.3, 61.4, 68.1, 82.4,

127.8, 128.1, 128.7, 136.6, 160.6, 162.3, 169.5, 178.2.

HRMS (ESI) calcd. for

C20H23N3O3 [M + H]+ 3541812, found 354.1800.
2-(4-(4-(Benzyloxy)-2-((1-methoxy-4-methyl-1-oxopentan-2-yl)amino)pyrimidin-5yl)-1H-1,2,3-triazol-1-yl)-3-methylbutanoic acid (4.21)

To a solution of 4.20 (0.1 mmol) and 4.22 (0.1 mmol) in tert-butanol (1 mL) was added a
solution of (+)-sodium L-ascorbate (0.1 mmol) in water (0.5 mL), and then a solution of
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copper(II) sulfate pentahydrate (0.05 mmol) in water (0.5 mL). The reaction mixture was
stirred at room temperature for 23 h. The reaction mixture was then concentrated under
reduced pressure. The residue was extracted between ethyl acetate and water. The
organic layer was washed with brine, dried over sodium sulfate, and the solvent was
removed under reduced pressure to afford the crude product as a yellow oil. Purification
by flash column chromatography on silica gel (methanol / dichloromethane, 1:20) affords
4.21 as a white solid (41 mg, 99%). 1H NMR (400 MHz, CDCl3) ppm 0.86 (dd, J = 32.4,
6.4 Hz, 6H), 1.02 (dd, J = 20.0, 6.8 Hz, 6H), 1.59–1.86 (m, 3H), 2.24 (dq, J = 13.2, 6.7
Hz, 1H), 3.68 (s, 3H), 4.11–4.20 (m, 1H), 4.40–4.54 (m, 1H), 5.37–5.59 (m, 1H), 7.27–
7.43 (m, 5H), 8.12 (s, 1H), 8.77 (s, 1H), 10.76 (br. s, 1H).

13

C NMR (100 MHz, CDCl3)

ppm 14.3, 14.5, 18.0, 19.77, 25.0, 29.3, 29.7, 31.2, 40.4, 52.5, 53.9, 61.4, 61.5, 68.7,
69.8, 70.0, 103.4, 103.4, 122.8, 128.1, 132.3, 138.5, 149.1, 159.6, 166.4, 172.9, 175.1,
179.9. HRMS (ESI) calcd. for C25H32N6O5 [M + H]+ 497.2507, found 497.2484.
2-Azido-3-methylbutanoic acid (4.22)

To a solution of L-valine (0.06 mmol), potassium carbonate (0.16 mmol), and copper(II)
sulfate pentahydrate (0.006 mmol) in methanol (2 mL) was added imidazole-1-sulfonyl
azide hydrochloride (0.07 mmol). The reaction mixture was stirred at room temperature
for 5 h. The reaction mixture was then concentrated under reduced pressure. The residue
was extracted between ethyl acetate and HCl (1M, aqueous). The organic layer was dried
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over sodium sulfate, and the solvent was removed under reduced pressure to afford the
crude product as a colorless oil. Purification by flash column chromatography on silica
gel (ethyl acetate/hexane, 1:1) affords 4.21 as a colorless solid (90%).

1

H NMR (400

MHz, CDCl3) ppm 1.01 (d, J = 6.7 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 2.17– 2.33 (m, 1H),
3.78 (d, J = 5.7 Hz, 1H), 11.80 (s, 1H).
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Chapter Five:
Design and Synthesis of Cyclic Urea HIV-1 Protease Inhibitor
5.1

Introduction

5.1.1

AIDS
Acquired immune deficiency syndrome (AIDS) was first identified on June 5th,

1981 in the USA (Gottlieb Michael, 2006). This syndrome is caused by the human
immunodeficiency virus (HIV), which is believed to have originated in non-human
primates in sub-Saharan Africa and then transferred to humans during the 20th century
(Gao et al., 1999). While it is hard to define the beginning of the AIDS epidemic, it has

Figure 5.1: Estimated number of people living with HIV globally, 1990–2007
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been estimated that during the 26 year period between 1981 and 2007 there have been
more than 25 million deaths as a result of AIDS infection. This averages out to almost 1
million AIDS related deaths per year.
Statistical data shows that the number of people living with HIV is still increasing
(Figure 5.1) (WHO, 2009); this implies that the number of deaths caused by AIDS is also
increasing.

In addition, this virus can be passed from mothers to children during

pregnancy or through breast milk (Kallings, 2008). As a result, children are becoming a
greater proportion of newly infected AIDS patients each year.
5.1.2

Efforts to treat or cure AIDS
Since the discovery of HIV, there have been tremendous efforts made towards

targeting this deadly virus. While there are several FDA approved drugs available to help
treat this disease, none of them can cure this disease.
In addition, those patients living in poor or developing countries, who account for
more than 90% of all HIV infected patients, cannot afford the astronomical cost of these
therapies (HIV/AIDS programme highlights, WHO report). Thus, designing synthetic
routes for novel small molecule HIV inhibitors remains an important goal. This report
will focus mainly on the HIV-1 virus, which accounts for about 90% of all HIV
infections.
5.1.3

Structure of HIV
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HIV belongs to a group of viruses called retro-viruses (Weiss, 1993), which carry
their genetic information in the form of RNA. The diagram of a mature HIV virion is
shown in Figure 5.2 (OracleThinkQuest). The center of the virion consists of two pieces
of single stranded viral RNA, which contains all of the virus’s genetic information. All
of the enzymes that are needed for the development of a new virion, such as the reverse
transcriptase, integrase, ribonuclease and protease are encoded in these RNA strands.
The virion is enclosed in a two layered network. The inner layer is called the conical
capsid which is composed of 2000 copies of a viral protein named p24. The outer layer is
called the protein matrix and is composed of a viral protein named p17. This kind of
multiple-layer enclosure exists to protect the integrity of the virion particles. These
layers are then surrounded by the envelope which is an outer membrane that is composed

Figure 5.2: Diagram of HIV
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of a phospholipid bilayer and is similar to a regular eukaryotic cell membrane.
Embedded in the viral envelope are about 70 copies of a viral protein known as Env
which is comprised of a cap and a stem. The cap is made from a cluster of three
glycoprotein gp120 molecules while the stem is made from a cluster of three
glycoproteins gp41 molecules. The function of the Env protein is to identify and bind to
receptor sites on the target cell’s membrane.
5.1.4

HIV replication mechanism
The targets of HIV are mainly the immune cells such as helper T cells (especially

CD4+T cells), macrophages, and dendritic cells. Figure 5.3 (wiki) shows the entire
replication process for the creation of a new HIV virion (Brik and Wong, 2003). HIV’s
entry to the host cell is mediated through the interaction between the gp120 protein on the
HIV membrane and the CD4 molecule on the target cell. The HIV virion absorbs the
glycoprotein on the host cell’s surface and then fuses the viral envelop with the cell
membrane. This leads to the HIV capsid’s entry into the host cell. Once the capsid has
bound to the host cell, the RNA strands and all the viral enzymes are injected into the
cell. The viral RNA is then copied into double stranded viral DNA by the reverse
transcriptase enzyme, which is then integrated into the host cell’s genome by another
enzyme known as integrase. Afterwards, the viral DNA is transcribed into viral mRNA
which is then translated into the viral polyprotein. The protease enzyme then helps to
finish the maturation process by hydrolyzing the viral polyprotein into individual viral
proteins. Finally, the mature viral protein, viral RNA and viral enzymes are packaged
together by a portion of the host cell’s membrane to form a new HIV virion.
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Figure 5.3: HIV replication cycle
5.1.5

Common targets to inhibit the HIV replication process
Studying the infection mechanism has led to the development of several

inhibitors, most of which target the viral enzymes. One of the most popular targets at the
present time is reverse transcriptase due to the fact that this enzyme does not naturally
exist in the human body thus minimizing the side effects of its inhibitors (Zheng et al.,
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2005). However, the reverse transcriptase is not actually a good target because of the
high replication rate of the virus (108-109 virions per day) along with a high error rate of
the HIV reverse transcriptase (~1 in 10K bases) which usually lead to a very high
resistance to the current drugs . On the other hand, another critical enzyme, the protease,
has become increasingly targeted because it is critical role for the development of a
mature HIV virion. It has been shown that the immature HIV viral polyprotein is not
infective (Kohl et al., 1988).
5.1.6

Structure of HIV protease
The HIV protease (HIV PR) is believed to belong to the family of aspartic

proteases. It contains 99 amino acids which function as a homodimer with only one
active site which is C2-symmetic when the protein is in the free form (Brik and Wong,
2003). Figure 5.4 shows the cocrystal structure of HIV PR complexed with inhibitor TL3. HIV PR’s active site is a cavity formed by the surrounding extended β-sheet region

Figure 5.4: Structure of HIV PR complexed with TL-3
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from both of the monomers. The ceiling of the cavity is Ile-50/Ile-50’, while the bottom
holds the Asp-25/Asp-25’ catalytic residues. With the exception of the Asp-25/Asp-25’,
Asp-29/Asp-29’, and Asp-30/Asp-30’ residues, this cavity is very hydrophobic.
5.1.7

HIV protease function mechanism
While the mechanism of this proteolysis is not very clear, it is generally accepted

that a catalytic water molecule acts as a nucleophile to attack the scissile bond instead of
the carboxylic group from Asp-25/Asp-25’ (Jaskolski et al., 1991). This then forms a
tetrahedral diol intermediate (Figure 5.5). Many potent transition-state inhibitors are
designed according to this mechanism.

Figure 5.5: Mechanism of HIV PR proteolysis
5.1.8

Cyclic urea as the HIV-1 protease inhibitor
In 1997, the DuPont Merck group found that cyclic ureas fit well in the HIV PR

active site cavity (Figure 5.6) (De Lucca et al., 1997); however there has been little work
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reported since. In this report, we plan to use cyclic urea as the HIV PR inhibitor basic
framework and extend the substitutents on it to get better binding affinity.

Figure 5.6: X-ray crystal structure of cyclic urea in the active site of HIV PR
5.1.9

Our design strategy
We would like to keep the six-membered cyclic urea ring since it sterically fits the

active site cavity very well. But we would like to attach more hydrophilic functional
groups (e.g. a hydroxyl group on the 4-position) to enhance the hydrogen bonding
interaction between our molecule and the Asp-29/Asp-29’ or Asp-30/Asp-30’ of the
HIV-1PR. Additional hydrophobic groups on the 5-position should help to increase Van
der Waals bonding or hydrophobic interaction between our molecules and the
hydrophobic cavity.
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In this report, we would also like to develop a general synthetic procedure for
making 4-hydroxyl cyclic urea. Eventually, we will be able to create a library of this type
of compound in order to test their bioactivities.
5.2

Results and Discussion

5.2.1

Retrosynthesis of 5-hydroxyl cyclic urea
The creation of a 5-hydroxyl cyclic urea is challenging because of the instability

of the geminal diamino functional group with an adjacent sp3 carbon center. This kind of
functional group is hard to form and easily decomposes. Our strategy in this report is to
try to rearrange an even more unstable 1,3-diazetidin-2-one b to achieve our desired
compound a (Scheme 5.1). As we can see, the four-membered 1,3-diazetidin-2-one b is
highly strained and the nitrogen atom in the ring adjacent to the Boc group is somewhat
of a good leaving group. The free amino group in the molecule could selectively open
one side of the four-membered ring to form a thermodynamically more stable
Scheme 5.1: Retrosynthesis of 5-hydroxyl cyclic urea
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six-membered ring a. This four-membered 1,3-diazetidin-2-one b could be made from a
2-oxo-1,3-diazabicyclo[2,2,0]hex-5-ene c molecule through oxidative cleavage of the
alkene followed by a Henry reaction. This bicyclic intermediate c could be synthesized
by photochemical electrocyclization from pyrimidin-2(1H)-ones d.
5.2.2 Synthesis of intermediate 5.3
Following this strategy, the following steps have been carried out (Scheme 5.2):
Scheme 5.2: Synthesis of the intermediate 5.3

The first major step of the synthesis is to make a variety of 1,4,6-trisubstituted
pyrimidin-2(1H)-ones 5.1 as the photochemical electrocyclization precursors. Table 5.1
shows all the pyrimidinone derivatives that have been synthesized so far.

Several

procedures have been developed, the most successful one is the condensation between
1,3-disubstituted 1,3-propanedione and N-substituted urea in acetic acid using ptoluenesulfonic acid as the proton source (Katritzky et al., 1982). Additionally, the use of
a Dean-Stark arm while refluxing has often been applied. Unfortunately, the yield of this
step is only poor to fair, e.g. 32% for R1 = Bn, R2 = iPr.
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Table 5.1: Analogs of the synthesized 1,4,6-trisubstituted pyrimidin-2(1H)-ones 5.1
R1

R2

Conditions

5.1a
5.1b
5.1c
5.1d
5.1e

Bn
Bn
Bn
Me
Bn

i

Pr
Ph
Me
Me
H

AcOH/PTSA reflux
AcOH /PTSA reflux
AcOH /PTSA reflux
AcOH /PTSA reflux
reflux

5.1f

Me

Ph

AcOH /PTSA reflux

Using the condensation reaction between 2,6-dimethyl-3,5-heptanedione and
benzylurea as a model (Table 5.1 5.1a), the first step of the cyclization is believed to be
the amino group of the N-benzylurea attacking one of the carbonyl groups on 2,6dimethyl-3,5-heptanedione. One of the big problems with this reaction is that it creates a
large quantity of side products (Scheme 5.3). This is due to the fact that in these high
temperature and acidic reactions conditions, benzylurea is prone to hydrolysis which then
generates benzylamine e. Benzylamnie then reacts with the protonated benzylurea to
form N,N’-dibenzylurea f which then precipitates out of solution thus making this side
reaction thermodynamically favorable. Additionally, this side reaction is very fast.
Scheme 5.3: Hydrolysis of N-benzylurea under high temperature acidic conditions
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Large amounts of precipitate can be seen within 30 minutes while the reaction time of the
cyclization is around 36 hours. In fact, pure N,N’-dibenzylurea f can usually be isolated
in large amount after the reaction. Due to these facts, the reaction of the diketone is less
favored than the reaction of benzylamine with N-benzylurea.
Several adjustments have been tried such as increasing the equivalence of
benzylurea, decreasing the reaction temperature below 90 °C to slow down the formation
of benzylamine, increasing the temperature to 150 °C to accelerate the cyclization, using
solvent free condition, and adding a small amount of dimethylformamide (DMF) to
prevent the precipitation. However, no improvement has been made so far. The good
thing is that this is the very first step of the synthesis, and the two starting material are
readily commercially available.

Therefore, the low yield of this reaction is not a

bottleneck for the whole synthesis.
It is worthwhile to mention that asymmetric diketones have been tried as well in
this reaction. However, this procedure lacks regio-selectivity and would yield a mixture
of products where the benzyl group on the urea would be found on either side of the
parent ring. Also, the two isomers formed here have very similar polarity which makes it
impractical to isolate them by chromatography on a large scale. Therefore, no further
work has been carried out using asymmetric diketones.
5.2.3

Photochemical electrocyclization of 1,4,6-trisubstituted pyrimidin-2(1H)-ones

5.1
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The second step, photochemical electrocyclization of the 1,4,6-trisubstituted
pyrimidin-2(1H)-ones to 2-oxo-1,3-diazabicyclo[2.2.0]hex-5-enes, is one of the key steps
of the synthesis (Scheme 5.4) (Nishio et al., 1981). While the photo reaction is a very
demanding step, it works very efficiently for those substrates which meet the
requirements of the reaction.
Scheme 5.4: Synthesis of the 1,3-diazetidine-2-one intermediate

The light source is the first crucial factor for this reaction to make 5.2. Several
lamps such as a Xenon lamp and a mercury vapor lamp (wavelength > 253nm) have been
tested, that they could not promote the reaction. We believe the failure of these reactions
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is because the photochemical cyclization is an equilibrium reaction; both starting
materials and products can absorb photons to go to the reverse of the reaction. The
product is a lot less stable than the starting material due to the high ring strain of the
bicyclic four-membered rings. Therefore, decomposition of the product is a favorable
reaction. One difference between the starting material and the product is that the starting
material has a conjugated double bond system while the product does not. This led us to
hypothesis that if we could find a light source that can provide photons with a wavelength
high enough, it is possible that only the starting material would be activated. Medium
pressure mercury lamps meet this requirement. Using a medium pressure mercury lamp
with a Pyrex filter provides a sufficient wavelength with a cutoff around 300 nm. This is
higher than any of the absorption wavelengths that the product has (Figure 5.7) so the
reaction should proceed in a highly favorable manner only towards the products.
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Figure 5.7: UV absorption of 5.1a
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The reaction is also dependent on the substitutents on the pyrimidinone ring.
Compounds 5.1d and 5.1f (Table 5.1) have no reaction because those compounds are too
polar to be dissolved in benzene, the common solvent for the photo chemical reaction.
Compound 5.1e, which did not have any solubility issue, did not work because the
normal photochemical cyclization is going through a triplet mechanism. The
unsubstituted 6-position on the pyrimidinone ring is not able to stabilize this triplet
intermediate. Compound 5.1b did not work however, is thought to be because of another
reason. For this substrate, when the four-membered product is formed, the double bond
in the four-memberded ring would be conjugated with the phenyl group; this would cause
the product to absorb photons with higher wavelength. Theoretically, if we can apply a
photon generator to generate photons with wavelength in certain ranges, we should be
able to get this substrate to work.
In summary, pyrimidinones 5.1 with good solubility in benzene (this can be
achieved by N-benzyl substitution), and with 6-position substitutuents, activated by
photons of proper wavelength (e.g. from medium pressure mercury lamp) should be able
to undergo this photochemical cycloaddition.
Then we ozonized the double bond to make compound 5.3. Other conditions
have been tested, e.g. NaIO4/OsO4, KMnO4 on solid support; but in both cases, the
double bond would not be fully cleaved, and an -hydroxyl ketone 5.8 was isolated as the
major product (Scheme 5.5).
Scheme 5.5: Side product of the oxidation of 5.2a
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It is worthwhile to point out that compound 5.3 is very moisture sensitive.
Spectroscopy normally detected both 5.3 and the molecule with one water added to form
a five-membered ring (Scheme 5.6).
Scheme 5.6: Equilibrium between 5.3 and its water added form 5.3’

5.3’ turned out to be problematic because the five-membered ring is so stable that
regular hydrolysis is not able to cleave the isobutyryl group on the nitrogen atom. We
chose to reduce the two new generated C,O double bond to cleave that isobutyryl group.
However, mild reductants, like sodium borohydride, could only reduce one of double
bond, to synthesize compound 5.4. Later, we found that LiBH4 is able to reductively
cleave both of the C,O double bond to prepare compound 5.5.
We also performed Henry reaction on 5.3 to synthesize compound 5.6; the nitro
group of 5.6 could then be easily reduced to afford compound 5.7.
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5.4

Experimental Procedures of selected compounds

1-Benzyl-4,6-diisopropylpyrimidin-2(1H)-one (5.1a)

To a solution of 2,6-dimethyl-3,5-heptanedione (46.7 mmol) in a mixture of acetic acid
(18 mL) and toluene (15 mL) was added N-benzylurea (74.2 mmol) and ptoluenesulfonic acid monohydrate (92.9 mmol). The reaction mixture was stirred under
reflux for 12 h. The precipitate was removed by vacuum filtration, and the filtrate was
concentrated under reduced pressure.

The residue was then extracted between

dichloromethane and water. The organic layer was dried over sodium sulfate, and the
solvent was removed under reduced pressure to afford the crude product a white solid.
Purification by flash column chromatography on silica gel (ethyl acetate/hexane, 3:1)
affords 5.1a as a white solid (4.0 g, 32%). 1H NMR (250 MHz, CDCl3) ppm 1.16 (d, J =
6.77 Hz, 6H), 1.28 (d, J = 6.91 Hz, 6H), 2.83 (m, 1H), 2.95 (m, 1H), 5.38 (s, 2H), 6.15 (s,
1H), 7.11–7.41 (m, 5H).

13

C NMR (75 MHz, CDCl3) ppm 17.4, 17.6, 19.6, 19.9, 29.5,

29.7, 47.4, 82.1, 115.8, 128.1, 128.7, 128.8, 135.6, 160.8, 166.7.
1-Benzyl-4,6-diphenylpyrimidin-2(1H)-one (5.1b)
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Compound 5.1b was prepared following the procedure described for 5.1a. Purification
by flash column chromatography on silica gel (ethyl acetate/hexane, 1:1) affords 5.1b as
a white solid (39%). 1H NMR (250 MHz, CDCl3) ppm 5.03 (s, 2H), 6.23 (s, 1H), 6.71–
7.19 (m, 13H), 8.07 (dd, J = 7.93, 1.68 Hz, 2H).

13

C NMR (75 MHz, CDCl3) ppm 49.6,

102.0, 127.4, 127.6, 128.1, 128.3, 128.5, 128.7, 129.6, 131.6, 134.2, 136.8, 137.5, 157.1,
160.0, 169.5.
1-Benzyl-4,6-dimethylpyrimidin-2(1H)-one (5.1c)

Compound 5.1c was prepared following the procedure described for 5.1a. Purification
by flash column chromatography on silica gel (ethyl acetate/hexane, 1:1) affords 5.1c as a
white solid (45%). 1H NMR (250 MHz, MeOD) ppm 2.38 (s, 6H), 5.37 (s, 2H), 6.45 (s,
1H), 7.14–7.44 (m, 5H).
1,4,6-trimethylpyrimidin-2(1H)-one (5.1d)

Compound 5.1d was prepared following the procedure described for 5.1a. Purification
by flash column chromatography on silica gel (ethyl acetate/hexane, 4:1) affords 5.1c as a
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white solid (55%). 1H NMR (250 MHz, MeOD) ppm 2.57 (s, 3H), 2.72 (s, 3H), 3.70 (s,
3H), 6.84 (s, 1H).
3-Benzyl-4,6-diisopropyl-1,3-diazabicyclo[2.2.0]hex-5-en-2-one (5.2a)

A solution of 5.1a (3.7 mmol) in 100 mL degassed benzene was irradiated with a medium
pressure mercury lamp using a Pyrex filter for 3 days. The reaction mixture was then
concentrated under reduced pressure to afford the crude material as a colorless oil.
Purification by flash column chromatography on silica gel (ethyl acetate/hexane, 1:7)
affords 5.2a as a colorless oil (0.88 g, 88%). 1H NMR (250 MHz, CDCl3) ppm 0.92 (d, J
= 6.75 Hz, 6H), 1.11 (d, J = 6.91 Hz, 6H), 1.96–2.13 (m, 1H), 2.50–2.64 (m, 1H), 4.40
(dd, J = 93.08, 15.26 Hz, 2H), 5.53 (d, J = 1.62 Hz, 1H), 7.19–7.38 (m, 5H).

13

C NMR

(75 MHz, CDCl3) ppm 21.3, 22.4, 30.4, 37.3, 47.8, 99.5, 126.5, 127.8, 129.1, 136.5,
158.2.
3-Benzyl-4,6-dimethyl-1,3-diazabicyclo[2.2.0]hex-5-en-2-one (5.2b)

Compound 5.2b was prepared following the procedure described for 5.2a. Purification
by flash column chromatography on silica gel (ethyl acetate/hexane, 1:7) affords 5.1c as a
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colorless oil (72%). 1H NMR (250 MHz, benzene-d6) ppm 1.12 (s, 3H), 1.73 (d, J = 1.68
Hz, 3H), 3.98 (dd, J = 63.00, 15.16 Hz, 2H), 5.18 (d, J = 1.68 Hz, 1H), 6.94–7.12 (m,
5H).
1-Benzyl-3-isobutyryl-2-isopropyl-4-oxo-1,3-diazetidine-2-carbaldehyde (5.3)

Through a solution of compound 5.2a (0.5g, 1.9 mmol) in 10 mL dichloromethane cooled
in acetone/dry ice bath was passed a stream of ozone until the light blue color persisted.
The reaction mixture was then flushed with argon (20 min), dimethylsulfide (3 mL) was
added, and stirring was continued at room temperature for 2 h. The reaction mixture was
then concentrated under reduced pressure. The residue was extracted between DCM and
water. The organic layer was dried over sodium sulfate, and the solvent was removed
under reduced pressure to afford the crude product as a yellow oil. Purification by flash
column chromatography on silica gel (ethyl acetate/hexane, 1:2) affords 5.3 as a colorless
oil (0.58 g, >90%). 1H NMR (250 MHz, CDCl3) ppm 0.84 (d, J = 6.92 Hz, 3H), 0.96 (d,
J = 6.85 Hz, 3H), 1.19 (d, J = 6.81 Hz, 3H), 1.25 (d, J = 6.96 Hz, 3H), 2.55 (td, J = 6.80
Hz, 1H), 3.29 (d, J = 6.80 Hz, 1H), 4.56 (dd, J = 48.58, 15.59 Hz, 2H), 7.25–7.42 (m,
5H).
1-benzyl-4-(1-hydroxy-2-nitroethyl)-3-isobutyryl-4-isopropyl-1,3-diazetidin-2-one
(5.6)
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To a solution of 5.3 (2.8 mmol) in ice cooled nitromethane (20 mL) was added
triethylamine (3.6 mmol). The reaction mixture was stirred at room temperature for
overnight. The reaction mixture was then concentrated under reduced pressure. The
residue was extracted between ethyl acetate and water. The organic layer was washed
with brine, dried over sodium sulfate, and the solvent was removed under reduced
pressure to afford the crude product as a yellow solid. Purification by flash column
chromatography on silica gel (ethyl acetate/hexane, 1:2) affords 5.3 as a white solid (0.58
g, 52%).
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Appendix A: Selected 1H and 13C NMR Spectra
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Methyl 2-(naphthalen-2-yl)acetate (2.1a)

154

3-Oxo-4-phenylbutanenitrile (2.2a)

155

4-(Naphthalen-1-yl)-3-oxobutanenitrile (2.2b)

O
CN

O
CN
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4-(Naphthalen-2-yl)-3-oxobutanenitrile (2.2c)

O
CN

O
CN
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5-Methyl-3-oxohexanenitrile (2.2d)

158

2-((Dimethylamino)methylene)-3-oxo-4-phenylbutanenitrile (2.3a)

159

2-((Dimethylamino)methylene)-4-(naphthalen-1-yl)-3-oxobutanenitrile (2.3b)

160

2-((Dimethylamino)methylene)-4-(naphthalen-2-yl)-3-oxobutanenitrile (2.3c)

161

2-((Dimethylamino)methylene)-5-methyl-3-oxohexanenitrile (2.3d)

162

2-((Dimethylamino)methylene)-4,4-dimethyl-3-oxopentanenitrile (2.3e)

163

4-(tert-Butyl)pyrimidine-5-carbonitrile

164

4-Benzylpyrimidine-5-carbonitrile (2.4b)

165

2-Methyl-4-(naphthalen-1-ylmethyl)pyrimidine-5-carbonitrile (2.4c)

166

4-iso-Butyl-2-phenylpyrimidine-5-carbonitrile (2.4d)

167

4-Benzyl-2-phenylpyrimidine-5-carbonitrile (2.4e)

168

4-tert-Butyl-2-phenylpyrimidine-5-carbonitrile (2.4f)

169

4-(Naphthalen-1-ylmethyl)-2-phenylpyrimidine-5-carbonitrile (2.4g)

N

N

CN

N

N

CN

170

2-Amino-4-benzylpyrimidine-5-carbonitrile (2.4h)

171

2-Amino-4-tert-butylpyrimidine-5-carbonitrile (2.4i)

172

4-Benzyl-2-methoxypyrimidine-5-carbonitrile (2.4j)

173

4'-Benzyl-4-(naphthalen-1-ylmethyl)-2'-phenyl-[2,5'-bipyrimidine]-5-carbonitrile
(2.6a)

174

4-Benzyl-4'-(naphthalen-1-ylmethyl)-2'-phenyl-[2,5'-bipyrimidine]-5-carbonitrile
(2.6c)
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CN
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175

4-Benzyl-2'-methyl-4'-(naphthalen-1-ylmethyl)-[2,5'-bipyrimidine]-5-carbonitrile
(2.6d)

N

N

N

N

CN

N

N

N
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CN
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4-(tert-Butyl)-2'-methyl-4'-(naphthalen-1-ylmethyl)-[2,5'-bipyrimidine]-5carbonitrile (2.6e)

N
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N
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5”-Cyano-4,4”-diisobutyl-4’-(1-naphthylmethyl)-2-phenylterpyrimidine (2.8a)

178

5”-Cyano-4”-isobutyl-4’-(1-naphthylmethyl)-4-(2-phenylmethyl)-2phenylterpyrimidine (2.8b)

179

5”-Cyano-4”-isobutyl-4’-(2-phenylmethyl)-4-(1-naphthylmethyl)-2phenylterpyrimidine (2.8C)

180

3-Hydroxy-4-phenylbutanenitrile (3.2)

181

N',3-Dihydroxy-4-phenylbutanimidamide acetate (3.3)

182

2-(2-Hydroxy-3-phenylpropyl)-4-isobutylpyrimidine-5-carbonitrile (3.4)

183

2-Bromo-1-phenylethanone (3.6)

184

2-Azido-1-phenylethanone (3.7)

185

2-(4-(1-Hydroxy-3-methylbutyl)-1H-1,2,3-triazol-1-yl)-1-phenylethanone (3.8)

186

3-(Dimethylamino)-2-(4-(1-hydroxy-3-methylbutyl)-1H-1,2,3-triazol-1-yl)-1phenylprop-2-en-1-one (3.9)

187

1-(1-(2-Amino-4-phenylpyrimidin-5-yl)-1H-1,2,3-triazol-4-yl)-3-methylbutan-1-ol
(3.10)

188

1-(1-(4'-isoButyl-2',4-diphenyl-[2,5'-bipyrimidin]-5-yl)-1H-1,2,3-triazol-4-yl)-3methylbutan-1-ol (3.11)

189

1-(Dimethylamino)-4-methylpent-1-en-3-one (4.1)

190

4-iso-Propylpyrimidin-2-amine (4.2)

191

5-Iodo-4-isopropylpyrimidin-2-amine (4.3)

192

4-(2-Amino-4-isopropylpyrimidin-5-yl)-2-methylbut-3-yn-2-ol (4.4)

193

5-(1-Benzyl-1H-1,2,3-triazol-4-yl)-4-isopropylpyrimidin-2-amine (4.6)B

194

1-(Dimethylamino)-4-methylhex-1-en-3-one (4.9b)

1-cyclopropyl-3-(dimethylamino)prop-2-en-1-one (4.9c)

195

3-(Dimethylamino)-1-phenylprop-2-en-1-one (4.9c)

196

2-(2-Benzylidenehydrazinyl)-4-phenylpyrimidine (4.10)

197

2-Azido-4-phenylpyrimidine (4.12)

198

3-Methyl-1-(1-(4-phenylpyrimidin-2-yl)-1H-1,2,3-triazol-4-yl)butan-1-ol (4.13)

199

4-(tert-Butyl)-2-chloropyrimidine-5-carbonitrile (4.14)

200

Carbamimidic chloride hydrochloride(4.15)

201

2-Chloro-4-isobutylpyrimidine-5-carbonitrile (4.16)

202

4-(Benzyloxy)-2-chloropyrimidine (4.17)

203

Methyl 2-((4-(benzyloxy)pyrimidin-2-yl)amino)-4-methylpentanoate (4.18)

204

Methyl 2-((4-(benzyloxy)-5-iodopyrimidin-2-yl)amino)-4-methylpentanoate (4.19)

205

Methyl 2-((4-(benzyloxy)-5-ethynylpyrimidin-2-yl)amino)-4-methylpentanoate (4.20)

206

2-(4-(4-(Benzyloxy)-2-((1-methoxy-4-methyl-1-oxopentan-2-yl)amino)pyrimidin-5yl)-1H-1,2,3-triazol-1-yl)-3-methylbutanoic acid (4.21)

207

2-Azido-3-methylbutanoic acid (4.22)

208

1-Benzyl-4,6-diisopropylpyrimidin-2(1H)-one (5.1a)

209

1-Benzyl-4,6-diphenylpyrimidin-2(1H)-one (5.1b)

210

1-Benzyl-4,6-dimethylpyrimidin-2(1H)-one (5.1c)

1,4,6-trimethylpyrimidin-2(1H)-one (5.1d)

211

3-Benzyl-4,6-diisopropyl-1,3-diazabicyclo[2.2.0]hex-5-en-2-one (5.2a)

212

3-Benzyl-4,6-dimethyl-1,3-diazabicyclo[2.2.0]hex-5-en-2-one (5.2b)

1-Benzyl-3-isobutyryl-2-isopropyl-4-oxo-1,3-diazetidine-2-carbaldehyde (5.3)

213

Appendix B: Selected HRMS

214

2-((Dimethylamino)methylene)-4-(naphthalen-1-yl)-3-oxobutanenitrile (2.3b)

215

2-((Dimethylamino)methylene)-4-(naphthalen-2-yl)-3-oxobutanenitrile (2.3c)

216

4'-Benzyl-4-(naphthalen-1-ylmethyl)-2'-phenyl-[2,5'-bipyrimidine]-5-carbonitrile
(2.6a)

217

5”-Cyano-4,4”-diisobutyl-4’-(1-naphthylmethyl)-2-phenylterpyrimidine (2.8a)

218

5”-Cyano-4”-isobutyl-4’-(1-naphthylmethyl)-4-(2-phenylmethyl)-2phenylterpyrimidine (2.8b):

219

N',3-Dihydroxy-4-phenylbutanimidamide acetate (3.3)

220

2-(4-(1-Hydroxy-3-methylbutyl)-1H-1,2,3-triazol-1-yl)-1-phenylethanone (3.8)

221

3-(Dimethylamino)-2-(4-(1-hydroxy-3-methylbutyl)-1H-1,2,3-triazol-1-yl)-1phenylprop-2-en-1-one (3.9)

222

1-(1-(2-Amino-4-phenylpyrimidin-5-yl)-1H-1,2,3-triazol-4-yl)-3-methylbutan-1-ol
(3.10)

223

1-(1-(4'-isoButyl-2',4-diphenyl-[2,5'-bipyrimidin]-5-yl)-1H-1,2,3-triazol-4-yl)-3methylbutan-1-ol(3.11)

224

5-Iodo-4-isopropylpyrimidin-2-amine (4.3)

225

4-(2-Amino-4-isopropylpyrimidin-5-yl)-2-methylbut-3-yn-2-ol (4.4)

226

2-Azido-4-phenylpyrimidine (4.12)

227

3-Methyl-1-(1-(4-phenylpyrimidin-2-yl)-1H-1,2,3-triazol-4-yl)butan-1-ol (4.13)

228

Methyl 2-((4-(benzyloxy)pyrimidin-2-yl)amino)-4-methylpentanoate (4.18)

229

Methyl 2-((4-(benzyloxy)-5-ethynylpyrimidin-2-yl)amino)-4-methylpentanoate (4.20)

230

2-(4-(4-(Benzyloxy)-2-((1-methoxy-4-methyl-1-oxopentan-2-yl)amino)pyrimidin-5yl)-1H-1,2,3-triazol-1-yl)-3-methylbutanoic acid (4.21)
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Appendix C: X-ray Crystallographic Data
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